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ABSTRACT 
 
Deepali Bang:  Oncogenic KRAS, GSK-3, NF-κB and TBK1: the interplay and 
consequences in promoting pancreatic and lung cancer 
(Under the direction of Dr. Albert Baldwin) 
 
 
 
The development of KRAS targeted therapy has evolved into targeting the 
complex signaling pathways activated downstream of oncogenic KRAS and associated 
with disease progression.  Recent focus has been made on targeting the constitutive 
activation of the transcription factor, NF-κB.  However, advancement of this therapeutic 
strategy is dependent on fully understanding the elusive mechanisms underlying 
constitutive NF-κB activity in KRAS driven cancers.  Glycogen synthase kinase-3 has 
previously been implicated in regulating pro-survival NF-κB signaling in pancreatic 
cancer cells through IκB kinase (IKK), but a distinction between roles of the individual 
isoforms, GSK-3α and GSK-β has not been done.  Moreover, TGF-β activated kinase 1 
(TAK1), an upstream regulator of IKK activity, was recently shown to regulate survival 
in KRAS positive colorectal cancers.  Here, we characterize mutant KRAS dependent 
GSK-3α regulation of NF-κB in pancreatic cancer cells.  Our data suggests that mutant 
KRAS upregulates GSK-3α, which promotes pro-survival canonical NF-κB via 
stabilization of TAK-TAB complex. We also provide initial evidence of GSK-3α 
dependent regulation of pro-survival non-canonical NF-κB in pancreatic cancer cells. 
Importantly, we show that pharmacological inhibition of GSK-3 suppresses growth of 
human pancreatic tumor explants with a concomitant loss of oncogenic gene expression 
like c-MYC and TERT. Collectively, we propose that GSK-3α regulates multiple arms of 
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NF-κB pathway in KRAS positive pancreatic cancer cells, identifying GSK-3α as 
promising therapeutic target. Recently, Tank Binding Kinase-1 (TBK1), an IKK-related 
kinase, has been implicated in survival of KRAS positive cancer cells. Here, we use a 
conditional TBK1 knockout mouse model with simultaneous activation of KRAS and 
inactivation of p53 in lung epithelial cells to provide initial evidence of a role of TBK1 in 
KRAS driven lung tumorigenesis.  These data broadens our understanding of NF-κB 
regulation in KRAS malignancies and implicates GSK-3α, TAK1 and TBK1 as emerging 
therapeutic targets.
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CHAPTER I 
 
INTRODUCTION 
 
 
1.1 Summary 
 
KRAS is frequently mutated and drives oncogenesis in a variety of human cancers 
(1,2). Unsuccessful attempts at direct targeting of KRAS has led investigators to consider 
targeting the downstream effector pathways of KRAS. The constitutive activation of the 
transcription factor NF-κB is among the many deregulated signaling pathways 
downstream of oncogenic KRAS that has been associated with multiple malignancies, 
including pancreatic cancer and lung cancer. Consequently, there has been focus on 
targeting constitutive NF-κB activity in these cancers (3,4) (5). Advancement of this 
therapeutic strategy is dependent on fully understanding the complex signaling events 
that drive NF-κB activity.  Recently Tank binding kinase-1 (TBK1), an IκB kinase (IKK) 
related kinase, which regulates NF-κB signaling, was shown to be important for KRAS-
driven cancers (6,7).  Here I provide new insight into elusive signaling events 
downstream of oncogenic KRAS that drive tumorigenesis in pancreatic and lung cancer 
and discuss glycogen synthase kinase-3α (GSK-3), and TGF-β activated kinase-1 
(TAK1), and TBK1 as potential therapeutic targets for these cancers. 
 The following will provide a general overview of KRAS signaling, NF-κB 
signaling in cancer and evidence of regulation by GSK-3 and TAK1, and TBK1 
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signaling.   Furthermore, I will review the functional significance of constitutive KRAS 
activity during oncogenesis and discuss the relevance to target this pathway in pancreatic 
and lung cancer.   
 
 
1.2 RAS proteins  
 
RAS proteins are proto-oncogenes that are frequently mutated in human cancers. 
The mammalian genome encodes three RAS genes that give rise to four ubiquitously 
expressed highly homologous proteins: HRAS (homologous to the oncogene of the 
Harvey murine sarcoma virus), KRAS- (homologous to oncogene of Kirsten murine 
sarcoma virus; K-RAS 4A and K-RAS 4B are splice variants of single gene) and NRAS 
(which does not have a retroviral homolog and was first isolated from a neuroblastoma 
cell lines) (8).  
The ~21kDa RAS proteins cycle between inactive (GDP)-bound and active 
(GTP)-bound conformations and function as molecular switches that couple cell surface 
receptor activation to intracellular signaling pathways. (1). The activation of RAS 
proteins, that is, the exchange of GDP with GTP, is an intrinsically slow process and is 
catalyzed by guanine nucleotide exchange factors (GEFs). However, this exchange is 
reversible. The inactivation of RAS involves the hydrolysis of the γ-phosphate of GTP to 
GDP catalyzed by GTPase-activating proteins (GAPs) and is irreversible. This 
inactivation of RAS activity by GAPs is the predominant target of the most of the 
oncogenic mutations of RAS. The resulting oncogenic versions of RAS proteins are 
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resistant to GAP-mediated GTP hydrolysis, which renders them constitutively active. 
GTP- bound RAS can interact productively with more than 20 effectors, including Raf, 
phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator 
(RALGDS), to regulate various cellular responses including proliferation, survival and 
differentiation (Figure 1.1).  
Newly synthesized RAS is a cytosolic protein that undergoes posttranslational 
modifications, which helps localize RAS to the correct subcellular compartment — 
principally the inner face of the plasma membrane. These modifications include the 
covalent attachment of a non-sterol isoprenoid from farnesyl pyrophosphate (FPP) to a 
cysteine residue that is close to the carboxyl terminus by prenylation. Farnesyltransferase 
inhibitors (FTIs) block this farnesylation, so RAS remains in the cytosol and is unable to 
function. After prenylation an endopeptidase, named RAS converting enzyme 1(RCE1), 
removes the end three amino acids from the carboxyl terminus of the protein. The new 
carboxyl terminus is then methylated by isoprenylcysteine carboxylmethyltransferase 
(ICMT), followed by palmitoylation and transfer to the plasma membrane. KRAS4B 
attaches to the plasma membrane without palmitoylation(1).  
The following section will review roles of RAS signaling in cancer with a focus 
on pancreatic and lung cancer. 
1.3 Role of RAS in Cancer 
 
Oncogenic roles of RAS family of GTPases are well established. Mutational 
activation of RAS occurs in over 30% of human cancer with pancreatic (90%), colon 
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(50%), thyroid (50%), lung (30%) and melanoma (25%) having the highest 
prevalence(8). Different tumor types have specific associations with individual RAS 
isoforms. For example KRAS, the most frequently mutated isoform in most cancers, is 
associated with pancreatic cancer, non-small cell lung cancer (NSCLC), colorectal cancer 
and seminoma. In contrast HRAS mutations are more strongly associated with tumors of 
the skin and of the head and neck and NRAS mutations are common in hematopoietic 
malignancies (9). All these mutations occur most frequently in codons 12, 13, or 61 
(Figure 1.2) and stabilize RAS in a constitutively active GTP bound conformation (2). 
Moreover, several other human cancers harbor alteration in factors that lie upstream of 
RAS, leading to over expression or mutational activation of growth factor receptor 
tyrosine kinase, such as epidermal growth factor (EGFR and ERBB2). Alternatively 
factors downstream of RAS are also commonly mutated, such as mutation of B-RAF in 
melanoma and colon cancer (1).  
Activated mutant RAS in cells can promote several of the characteristics of 
malignant transformation. These include increased proliferation due to upregulation of 
several transcription factors that are required for cell cycle entry and progression, 
including FOS, JUN, ELK1, ATF2 and NF-κB. These factors in lead to induction of cell 
cycle regulators such as cyclin D1, which leads to inactivation of the retinoblastoma (RB) 
pathway, and suppression of cell- cycle inhibitors such as KIP1 (9). As such, cyclin D1-
deficient mice are resistant to developing mammary cancers and squamous tumors that 
are induced by the HRAS oncogene (10). In addition, RAS transformed cells become 
desensitized to apoptosis through PI3K and RAF signaling. Activated PI3K leads to 
downregulation of the pro-apoptotic protein BAK1, and augments IAP levels through the 
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activation of NF-κB (11). Oncogenic RAS-induced effector pathways also impinge on 
metabolic reprogramming of cancer cells, a known hallmark of cancer (12). The effect on 
cellular metabolism is exerted through concurrent activation of MAP3K and PI3K 
leading to upregulation of HIF1α (13), and through upregulation of autophagy(14,15), 
both of which stimulate a glycolytic shift. RAS effector pathway also lead to the 
induction of angiogenesis, mainly by means of ERK mediated transcriptional 
upregulation of angiogenic factors (like VEGF), matrix metallo proteinases (16). 
Oncogenic RAS can also subvert antitumor immunity by down-regulating expression of 
antigen-presenting major histocompatibility complexes (MHC) on cancer cells(17), and 
through the recruitment of immunosuppressive regulatory T cells (TRegs) and myeloid-
derived suppressor cells (MDSCs) to the tumor site(18,19). Finally RAS -dependent 
signaling pathways including the RAS–MAPK, RAS–PI3K, RAS–RAL GTPase and 
RAS–RHO GTPase have been demonstrated to have an essential role in metastatic 
progression (9). Targeting RAS and its effector pathway could, therefore, have a potential 
impact on almost all aspects of malignancy. 
The next two sections review the role of KRAS in driving two of the most 
difficult to treat cancers:  Pancreatic and lung cancer.  
1.3.1 Role of KRAS in pancreatic ductal adenocarcinoma 
 
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of 
the pancreas and is the fourth leading cause of cancer-related deaths in the United States 
(20).  KRAS, is invariantly among the most frequently mutated genes associated with 
human pancreatic cancers. Annually, the number of victims of the disease approaches the 
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number of new diagnoses. Approximately 46,420 new cases of pancreatic cancer will be 
expected in 2014, while 39,590 patients are estimated to die from this disease(20). The 
nucleoside analog, gemcitabine, is among the most active single-agent chemotherapy 
currently used to treat advanced stages of pancreatic cancer and is considered to be the 
first-line therapy for patients (21).  Lack of efficient early-detection methods, aggressive 
metastatic potential, and chemotherapy resistance all account for the dismal mortality rate 
(a 5-year survival rate of 6% is associated with pancreatic cancer (20). Therefore, it is 
critical to advance our understanding of the molecular pathogenesis of pancreatic cancer 
in order to develop effective targeted chemotherapies to treat this disease.   
Extensive histological and genetic studies have characterized the pathogenesis of 
pancreatic cancer into three early stages of pre-invasive lesions known as pancreatic 
intraepithelial neoplasia (PanIN) (Fig. 1.3) (22). Recent tumor genome sequencing 
studies have established the prevalence of mutant KRAS in PanINs, (23), and in 
pancreatic cancer(24,25) with increased precision. The most common mutation in KRAS 
is one amino-acid substitution in position 12 of the KRAS protein, leading to a glycine 
(G) to aspartic acid (D) substitution, although other variants, such as G to V are also 
common (Table 1.1) (26-29). Malignant progression from PanINs to invasive and 
metastatic disease is accompanied by the early acquisition of activating mutations in the 
KRAS oncogene, which occurs in >90% of cases, and subsequent loss of tumor 
suppressors including INK4A/ARF, TP53, and SMAD4 (30). Genetically engineered 
mouse models (GEMM) have provided evidence for oncogenic KRAS (KRASG12D) as 
a major driver in PDAC initiation and maintenance, with the aforementioned tumor 
suppressor genes constraining progression (31-33) (34,35).  
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1.3.2 Role of KRAS in lung cancer 
 
Lung cancer is the leading cause of cancer-related deaths worldwide (20). The 
two major forms of lung cancer are non-small cell lung cancer (about 85% of all lung 
cancers) and small-cell lung cancer (about 15%). Non-small cell lung cancer (NSCLC) 
has amongst the worst prognoses of all human malignancies. Non-small cell lung cancer 
can be divided into three major histologic subtypes: squamous-cell carcinoma, 
adenocarcinoma, and large-cell lung cancer; adenocarcinoma is the most common type 
accounting for >40% of all lung cancers (36). Analysis of resected tumors has revealed 
several frequent molecular changes: KRAS is mutated to an activated form in 30% of 
NSCLCs, EGFR is up-regulated in 10%–40%, the p53 tumor suppressor gene is mutated 
or deleted in 50%, and the INK4A/ARF locus is often deleted or hypermethylated (Table 
2).  
KRAS mutations are also observed in a substantial number of sporadic and 
chemically induced lung adenocarcinomas in mice (37-39). Further evidence for the role 
of KRAS in oncogenesis of lung cancer comes from mouse studies where expression of 
mutant KRAS is sufficient to cause transformation and development of adenocarcinoma 
(40,41) . 
Most KRAS mutations in lung adenocarcinoma are G→T transversions 
(substitutions of a purine for a pyrimidine) and affect exon 12 (in 90% of patients) or 
exon 13. As seen in pancreatic cancers, KRAS mutations appear to be an early event in 
lung cancers (e.g., detectable in the preinvasive lesions of atypical adenomatous 
hyperplasia and bronchoalveolar carcinoma) that precedes lung adenocarcinoma. 
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Importantly, activating point mutations in KRAS are associated with poor prognosis and 
therapy resistance (42,43). 
Taken together, the role of oncogenic KRAS in initiating and driving pancreatic 
and lung adenocarcinomas is well established. Thus targeting RAS and its effector 
pathway has been a focus for cancer biologists seeking to develop rational anti-cancer 
drugs as explained in the next section. 
1.4 Targeting RAS as a therapeutic approach to cancer 
 
For RAS as a therapeutic target, post-translational modifications, known to be 
required for RAS biological activity has been a very attractive target(44). In this regard, 
Farnesyl transferase that catalyse attachment of farnesyl isoprenoid group to RAS 
proteins were an obvious target. Number of highly effective Farnesyl transferase 
inhibitors (FTIs) have been identified that inhibit cell growth of a large variety of cancer 
cell lines in vitro and in vivo as tumor xenografts (45,46). However, KRAS, the most 
frequently mutated RAS oncogene in human cancers, can undergo alternative prenylation 
by GGTase I in FTI-treated cells, resulting in a persistent membrane localization of 
KRAS and concomitant upregulation of downstream signaling. Inhibition of the two post 
prenylated enzymes RCE1 and ICMT has also met little success (47,48).  While blocking 
RCEI activity in tumor cells or mouse models has shown only moderate effects, 
inhibition of ICMT affects multiple pathways besides RAS leading to toxic effects like 
atherosclerotic vascular injury (8,46). 
Taken together, strategies that compromise RAS post-translational processing 
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have, for the most part, not been rewarding. The idea of preventing RAS expression by 
antisense or RNA interference seems promising, but the successful application of this 
technology is currently limited by lack of efficient delivery, uptake, and gene silencing. 
Additionally the observation that tumor cells expressing mesenchymal markers are 
relatively independent on the presence of RAS oncogene has raised questions on the 
potential of elimination of RAS expression as an effective cancer therapy (49). 
Collectively, developing therapeutic agents to directly block oncogenic RAS 
activity has been a challenging and unsuccessful endeavor, for reasons discussed above. 
Therefore, a great deal of effort has been applied to developing therapies that target 
effector pathways downstream of RAS (Figure 1.1). Understanding which effector 
pathways are required for RAS-driven oncogenesis is critical for determining which 
pathways should be targeted for therapeutic purposes. As a result, new insight has 
emerged in comprehending the network of deregulated signal transduction pathways 
downstream of oncogenic KRAS.   Most RAS effector pathways are comprised of kinase 
cascades, providing multiple nodes for potential therapeutic intervention. Several RAS 
effectors have been identified and comprehensively described, including RAF-MEK-
ERK and PI3K signaling (1,8,46). In the case of lung and pancreatic cancers, constitutive 
signaling from PI3K/AKT, EGFR, and RAS/RAF/MAPK pathways have all been 
implicated to play key roles in the development and progression of these cancers (42) 
(50).  Interestingly, these deregulated pathways utilize molecular crosstalk with the 
transcription factor NF-κB (50). Thus, focus has been made on targeting constitutive NF-
κB signaling as an alternative therapeutic strategy to treat these adenocarcinomas (4,5,51-
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53).  However, advancement of this strategy is dependent on fully understanding the 
signaling events that drive constitutive NF-κB activation. 
1.5 Constitutive NF-κB in Cancer 
 
NF-κB was originally discovered over 25 years ago as a nuclear factor that binds 
the immunoglobulin κ enhancer sequence in B-cells(54).  NF-κB has since been 
characterized as an inducible family of conserved dimeric transcription factors consisting 
of: RelA/p65, RelB, c-Rel, p52 (p100 precursor), and p50 (p105 precursor) (Fig. 1.4). 
The N-terminal region of NF-κB consists of a highly conserved, 300 amino-acid, Rel 
homology domain (RHD) which promotes dimerization, nuclear localization, and DNA 
binding.  A C-terminal transactivational domain (TAD) is located within RelA/p65, RelB, 
and c-Rel and facilitates NF-κB transcriptional activity upon inducible posttranslational 
modifications. The C-terminal region of the precursor NF-κB members (p100 and p105) 
contains an inhibitor ankryin repeat domain which can undergo proteolytic cleavage, to 
generate the active p52 and p50 subunits.  Although processing of p105 to p50 is known 
to be constitutive, p100 to p52 processing is tightly regulated (55).   
The inducible activity of NF-κB plays a central role in the regulation of diverse 
biological processes such as inflammation, immunity, development, cell proliferation, 
and survival (56).  The NF-κB target genes that drive these biological processes include 
cytokines (i.e. IL-6, IL-12 TNF-α, and LTβ), chemokines (i.e. MCP1, IL-8, RANTES, 
and MIP-1α), and adhesion molecules (i.e. ICAM and VCAM)(56).  
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In resting cells, NF-κB is rendered inactive and sequestered in the cytoplasm 
through interaction with an inhibitor protein called IκB. NF-κB is typically activated 
through one of two distinct pathways. Canonical NF-κB activity can be triggered by 
various stimuli including inflammatory cytokines, microbial infection, DNA damage, and 
mitogens(57).  These stimuli promote the activation of the IκB kinase (IKK) complex 
which consists of a regulatory subunit (IKKγ) and two catalytic, serine/ threonine kinase 
subunits (IKKα and IKKβ). Once this complex is activated, IKKβ phosphorylates NF-
κB-bound IκB proteins which leads to its rapid ubiquitination and subsequent 
proteosomal degradation (58,59).  Consequently, NF-κB dimers can undergo nuclear 
translocation and bind to κB consensus sequences within target gene promoters (Fig. 
1.5).   
In the non-canonical NF-κB signal transduction, diverse stimuli such as B-cell 
activating factor (BAFF) and CD40 ligand, trigger a signaling cascade which activates 
the NF-κB inducing kinase (NIK) (55).  NIK drives the activation of IKKα homodimers 
which subsequently phosphorylates p100, leading to its proteolytic processing and the 
generation of p52 (Fig. 1.5) (60). As a result, activated RelB/p52 heterodimers can 
translocate to the nucleus to drive NF-κB-dependent gene transcription.   
Deregulated NF-κB activity has been linked to chronic inflammatory diseases (i.e. 
rheumatoid arthritis and lupus) and tumorgenesis (61). In cancer NF-κB is known to 
promote angiogenesis, metastasis, cell survival, cell cycle progression, and insensitivity 
to growth inhibition- which are all well described hallmarks of cancer (12).Constitutive 
NF-κB activation can be observed in a wide range of malignancies including those of 
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breast, colon, lung cancer, melanoma, multiple myeloma, esophageal adenocarcinma, and 
pancreas (62) (63). NF-κB is often thought to serve as the bridge between inflammation 
and cancer (63). In colitis-associated cancer, deletion of IKKβ inhibited transcription of 
proinflammatory cytokines and reduced tumor formation in vivo (64). 
Due to the role of NF-κB in tumorigenesis, NF-κB is an attractive target for 
cancer therapeutics.  Several IKKβ inhibitors are available to determine the efficacy of 
IKK/NF-κB inhibition in various types of cancer.  For example, treatment of lung tumor 
cells ex vivo with an IKKβ inhibitor reduced NF-κB activation (5), and treatment of 
animals with mutant KRAS-driven lung tumors resulted in tumor regression and 
prolonged survival (65). However, IKKβ inhibition also leads to lymphocyte toxicity (66) 
and granulocytosis (67) in healthy animals.  Further studies are required to determine the 
effects of IKKβ inhibition in other in vivo cancer models, and whether the benefits 
outweigh the side effects. 
1.5.1 RAS and NF-κB 
 
Studies from our group revealed that oncogenic H-RAS induces cellular 
transformation in fibroblasts by activating NF-κB (68), and NF-κB activation is required 
to suppress oncogenic H-RAS–induced apoptosis(69). Other studies have shown a 
correlation between increased NF-κB activity and expression of oncogenic K-RAS 
(70,71). Duran and colleagues (72) showed a mechanistic link between K-RAS, IKK, and 
NF-κB through the signaling adaptor p62. Meylan et al. (53) demonstrated that inhibition 
of NF-κB signaling led to an apoptotic response in p53-null lung cancer cell lines, while 
inhibition of the pathway in vivo in the context of KRASG12D–driven lung tumorigenesis 
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showed reduced tumor development both at the time of tumor initiation and after tumor 
progression. Additionally, our group (5) showed that deletion of NF-κB subunit 
p65/RelA reduced the number of KRAS– induced lung tumors both in the presence and 
absence of p53, and the tumors that emerged in the absence of p65/RelA showed a higher 
number of apoptotic cells, reduced spread, and showed lower grade. In KRAS-driven 
pancreatic cancers, both canonical and non-canonical NF-κB have been found to be 
constitutively active and promote survival and chemoresistance (51,73-78). Recently 
knockout of IKKβ was shown to suppress tumor growth/progression in a KRAS/INK4a 
null animal model of pancreatic cancer (79). Oncogenic RAS also induces inflammatory 
cytokines that activate NF-κB and STAT3. For example, KRAS-driven non-small cell 
lung cancers (NSCLC) (7) and pancreatic ductal adenocarcinomas (PDAC) (8) engage 
cell autonomous IL-1 signaling. Recently IKK related kinases, TBK1 and IKKe have also 
been implicated in promoting survival of KRAS-driven tumors (6,80).  
Collectively, these reports and others underscore the need to target IKK and NF-
κB as a chemotherapeutic strategy in KRAS-driven cancers. The following sections will 
discuss the regulation of NF-κB by two versatile serine theronine kinases, transforming 
growth factor β-activated kinase 1 (TAK1) and glycogen synthase kinse-3 (GSK-3).  
1.6 TAK1-dependent regulation of NF-κB  
 
 
TAK1 belongs to the evolutionarily conserved mitogen-activated protein kinase 
kinase kinase (MAP3K) family and was originally discovered to function within the 
transforming growth factor-β (TGF-β) signaling pathway(81).  In addition to the TGF-
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β ligand family, this versatile serine/theronine kinase can be activated by a diverse set of 
stimuli such as interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), and 
lipopolysaccharide (LPS) (82,83).  Upon receptor activation, TAK1 can initiate 
individual downstream signaling cascades culminating in the activation of IKK and 
MAPKs (JNK and p38) (83,84).  TAK1 plays a central role in NF-κB signaling through 
direct phosphorylation of IKKβ (85), and promotes expression of various cellular stress 
and inflammatory-response genes.   
TAK1 activity is dependent on various phosphorylation events and interaction 
with essential signaling adapters called TAK1 binding proteins (TAB1, TAB2, TAB3 and 
TAB4) (Fig. 1.6) which facilitate autophoshorylation at Thr178, Thr184 and Ser 192 
following stimulation (86-88). Notably, TAB proteins have been demonstrated to play a 
crucial role in facilitating TNF-α and IL-1β-dependent activation of NF-κB and MAPK 
pathways (87,89).   
Deregulated TAK1 signal transduction has been associated with constitutive NF-
κB activity in human cancer cell lines (90,91). TAK1 was shown to promote cell 
proliferation in human head and neck squamous cell carcinnoma (HNSCC) cell lines by 
mediating constitutive NF-κB activity (90). Additionally, TLR2 overexpression was 
reported to promotes constitutive TAK1/ NF-κB signaling and cell invasion in MDA-
MB-231 cells (91).  Recently TAK1 has been shown to be important for survival of 
KRAS-dependent colorectal cancers and to play an important role in the chemoresistance 
of pancreatic cancers (92,93).Taken together, TAK1 plays a key role in cross regulating 
the complex pathways leading to NF-κB activity in human cancers, and could thus, be 
considered a novel therapeutic target.  
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1.7 GSK-3-dependent NF-κB Signal Transduction   
  
Glycogen synthase kinase-3 (GSK-3) was discovered 25 years ago as a 
serine/threonine kinase involved in the downregulation of glycogen biosynthesis through 
the phosphorylation and inactivation of glycogen synthase (94). There are two 
mammalian isoforms, GSK-3α and GSK-3β, that are encoded by two independent genes 
and share 85% overall sequence identity and 93% similarity within the catalytic domain 
(95,96) (97).  A significant difference between GSK-3 isoforms is observed in the N-
terminal region where GSK-3α possesses an extended glycine-rich tail (Fig. 1.7).  
Although purified GSK-3 isoforms exhibit similar substrate properties (96), evidence 
from GSK-3α and GSK-3β deficient mouse models suggest non-overlapping substrate 
specificities10.  GSK-3α deficient mice exhibit enhance glucose and insulin 
sensitivity(98), while GSK-3β deficiency is embryonic lethal at day E13.5 due to liver 
degeneration (99).   
Unlike most protein kinases, GSK-3 is constitutively active in resting cells and is 
primarily regulated by various upstream signaling events that lead to the phosphorylation 
and inactivation of GSK-3 (Fig. 1.8). AKT promotes the serine phosphorylation (S9/21) 
and inactivation of both GSK-3 isoforms downstream of PI3K (100). GSK-3 is most 
recognized for its role in Wnt/β-catening pathway where its leads to β-catenin 
phosphorylation and subsequent proteosomal degradation. Canonical Wnt/ β-catenin 
signaling is an evolutionarily conserved pathway which plays a key role during 
development by regulating cell growth, differentiation, and polarity (97).  
 16 
GSK-3 is a multi-tasking kinase that plays an intricate role in diverse signaling 
pathways.  As a consequence, GSK-3 is known to have an expanded range of substrate 
specificities (Fig. 1.8). The consensus motif for GSK-3 substrates is Ser/Thr-X-X-X-
Ser/Thr (X represents any amino acid).  GSK-3 has the unique ability of targeting 
substrates that have previously phosphorylated (primed) at the C-terminal Ser/Thr 
residues of the consensus motif (101). Interestingly, there has been an increasing body of 
literature implicating the role GSK-3 plays in cross regulating the activity of NF-κB. 
The first evidence of GSK-3-dependent regulation of NF-κB was provided by 
James Woodgett and collegues (99). Interestingly, embryonic lethality was observed in 
GSK-3β homozygous null mice between E13.5 and E14.5 days due to TNF-α-dependent 
hepatocytes apoptosis.  Notably, this phenotype is consistent with the homozygous 
deletion of the p65 subunit of NF-κB (102) and IKKβ (103).  To demonstrate GSK-3β-
dependent NF-κB regulation, mouse embryonic fibroblasts from GSK-3β-deficient mice 
were also shown to be defective in TNF-α-induced NF-κB activation (99).    
The exact mechanism of how GSK-3β regulates inducible NF-κB activity remains 
controversial. Reports have implicated GSK-3β to either regulate early stages of NF-κB 
activation (IKK complex activation and IκB degradation) or later stages (NF-κB 
transcription activity at target gene promoters).  Bharat Aggarwal and colleagues reported 
that GSK-3β null MEFs are defective in inducing IKK activity and IκBα 
phosphorylation/ degradation in response to TNF-α, IL-1β, and lipopolysaccharide (104).  
In contrast with this report, work from our lab and others have suggested that GSK-3β 
deficiency, as well as, pharmacological GSK-3 inhibition diminishes cytokine-induced 
NF-κB activity at the transcriptional complex level (99,105,106). We also reported the 
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role of GSK-3 in regulating IKK-driven NF-κB activity in pancreatic cancer cells (75).  
Further evidence showed that GSK-3β can directly target the phosphorylation of p65 
(amino acids 354-551), thus promoting NF-κB transactivation (106).  Overall, GSK-3β 
plays an essential role in cross regulating cytokine-induced NF-κB activation through 
either an IKK-dependent or independent mechanism. Due to the known pro-survival 
functions of NF-κB, studies have also focused on the potential role GSK-3 may play 
during carcinogenesis.   
1.7.1 GSK-3 Inhibitors as a Targeted Therapy for Cancer  
 
GSK-3 has been linked to deregulated signaling pathways leading to the 
pathogenesis of various human diseases.  Consequently, GSK-3 has emerged over the 
years as a therapeutic target for Alzheimer’s disease, bipolar disorder, dementia, and 
noninsulin-dependent diabetes mellitus (NIDDM) (107).  Moreover, there is increasing 
evidence linking aberrant GSK-3 signaling with the development of cancer.  GSK-3 is 
generally considered a tumor suppressor due to its role in suppressing the oncogenic 
effects of the Wnt/ β-catenin pathway in colorectal cancer (108).  However, this 
paradigm has been challenged by recent reports that suggest GSK-3 plays an oncogenic 
role by facilitating cell growth, survival, and constitutive NF-κB activity.  Advancement 
of these studies was made possible by the development of pharmacological GSK-3 
inhibitors. 
Lithium was the first tool discovered used to inhibit GSK-3 activity (109).  
However, the broad kinase specificity range of lithium has prompted pharmaceutical 
companies to develop small molecule inhibitors with increased specificity for GSK-
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3(110).  SB 216763 (ATP-competitive, IC50 = 34.3 nM), SB 415286 (ATP-competitive, 
IC50 = 77.5 nM), AR-A014418 (ATP-competitive, IC50 = 104 nM), and TDZD-8 (non-
ATP-competitive, IC50 = 2µM) are among the most recently developed GSK-3 inhibitors 
that have been implicated to have therapeutic potential in human cancers (111-113).  
Notably, these inhibitors do not provide significant selectivity between GSK-3α and 
GSK-3β isoforms due to sequence identity within the kinase domain. 
Studies within the past five years have implicated GSK-3 inhibitors as a potential 
targeted therapy for prostate cancer, multiple myeloma, leukemia, and pancreatic 
cancer(114-117).  Although the mechanism of action remains unclear, GSK-3 inhibitors 
may function partially by suppressing constitutive, pro-survival signaling to NF-κB. Our 
lab and others have provided evidence of GSK-3-dependent constitutive pro-survival 
IKK-NF-κB activity in pancreatic cancer cell lines (75,118,119).  These reports 
demonstrated that GSK-3 is active in pancreatic cancer cells, and that GSK-3 inhibition 
suppresses constitutive NF-κB reporter activation and target gene expression. 
Furthermore, the suppression of constitutive NF-κB activity following GSK-3 inhibition 
correlated with decreased cell growth/ survival in both in-vitro (75,118) and in-vivo 
models (119). All the above studies either focused on GSK-3β or did not distinguish 
between the two isoforms, GSK-3α and GSK-3β, however, a recent study implicated 
GSK-3α in promoting acute myelogenous leukemia (120). Taken together, these reports 
establish GSK-3 inhibition as a potential therapeutic strategy for cancer but needs further 
investigation to dissect the contribution of the individual isoforms in various 
malignancies. 
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1.8 Role of non-canonical IKK, TBK1 in cancer 
 
In addition to the conventional IKKs, a related pair of non-canonical kinases, 
IKKε (IKKi, encoded by IKBKE) and TBK1 (NAK), have been identified as important 
mediators of both inflammatory and oncogenic signaling. TBK1 was identified as an 
interaction partner with the scaffolding molecule, TRAF-associated NF-κB activator 
(TANK) (121). It comprises of an N-terminal kinase domain, an ubiquitin- like domain, a 
C-terminal LZ and a HLH motif (Fig. 1.8) and is a critical inducer of interferon signaling 
in response to viral infection (80). TBK1 can be activated in a TLR dependent or 
independent manner by viral components or ds RNA/DNA respectively, leading to 
phosphorylation of interferon regulatory factors (IRFs) 3, 5 and 7. This allows for 
heterodimerization and nuclear translocation of the IRFs and induction of pro-
inflammatory and antiviral genes, IFNα/β. 
TBK1 is highly expressed in lung, breast and colon cancers and a TBK1 mutation, 
P675L, was recently identified in lung adenocarcinoma (6). In regards to the role of 
TBK1 downstream of oncogenic KRAS, the RAS-like RalB mediated activation of TBK1 
was shown to promote TBK1 assembly with the exocyst complex, where it facilitates 
transformation through the phosphorylation of the secretory protein Sec5. Importantly, 
suppression of either TBK1 or Sec5 induced apoptosis in RAS-transformed cells, and 
expression of oncogenic alleles of KRAS induced cell death in TBK1-deficient murine 
embryonic fibroblasts (122).  Additionally TBK1 was found to be important for AKT 
signaling, an important downstream effector of KRAS, through direct phosphorylation of 
AKT (123). TBK1 has been shown to sustain KRAS-dependent cancer cell viability 
through regulation of NF-κB subunit c-Rel (6)and promote tumor survival in murine lung 
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cancer by activating autocrine cytokine signaling of CCL5 and IL-6 (7). Moreover, TBK-
1 dependent non-canonical NF-κB signaling has been observed to contribute to 
autophagy addiction in KRAS driven NSCLC (124).  
To sum it all, the above results identify TBK1 as a novel and effective target 
downstream of oncogenic RAS highlighting the need to further investigate the functions 
of TBK1. 
1.8.1 Mouse Models of TBK1 
 
Studies of TBK1 function have been hindered by the fact that homozygous 
deletion of TBK1 is lethal in utero at approximately embryonic day 14.5 as a result of 
massive liver degeneration and apoptosis, a phenotype similar to knockout of p65(125). 
This embryonic lethality can be rescued by breeding these animals onto a TNF-/-  or 
TNFR1-/- background and thus most studies in which TBK1 deficient mice were used, 
such animals were TBK1-/- TNF-/-  or TBK1-/- TNFR1-/- double knockouts. Recently a 
conditional TBK1fl/fl model was crossed with B-cell specific Cre recombinase to generate 
TBK1-BKO mice heterozygous for the Cre gene, and with B-cell specific ablation of 
TBK1(126). Using these mice, TBK1 was shown to negatively regulate non-canonical 
NF-κB signaling by phosphorylating NIK leading to its degradation. In another study, a 
conditional TBK1fl/fl was crossed with a line of transgenic mice that carry the Prml-Cre 
recombinase transgene. This transgene caused conversion of the TBK1fl allele to TBK1Δ 
in the sperm of male mice by Cre-mediated deletion of exon 2. TBK1Δ allele expressed 
low amounts of an inactive and much smaller in size TBK1 protein and mice 
homozygous for this allele (TBK1Δ/Δ) were found to be viable on a 129S5 background 
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but not C57BL6 (127). Thus a true TBK1 deficient mouse model is still not available to 
establish the role of TBK1 in KRAS driven oncogenesis in vivo. 
1.9 Conclusions 
 
Despite continuous research efforts, tumors harboring KRAS mutations, such as 
pancreatic and non-small cell lung adenocarcinomas, remain the most difficult to treat 
and lack any effective targeted therapies. The evolution of pancreatic and lung cancer 
chemotherapy is dependent on the development of agents that specifically target 
deregulated molecular pathways downstream of mutations associated with disease 
progression (128).  Pancreatic and lung cancers are among many human malignancies 
that utilize constitutive NF-κB signaling. GSK-3 has been demonstrated to regulate 
constitutive IKK and the subsequent pro-survival NF-κB activity in pancreatic cancer 
cells, while the IKK related kinase TBK1 has been implicated in the survival of lung 
cancer cells through c-Rel. Therefore, chemotherapeutic agents that target GSK-3 and 
TBK1 activity may be efficacious in the treatment of these malignancies. Advancement 
of this therapeutic strategy requires full understanding of the complex molecular 
mechanisms that regulate constitutive GSK-3-IKK-NF-κB activity in pancreatic cancer 
cell and TBK1-cRel activity in lung cancer cells.  
This chapter reviewed the critical roles GSK-3, TAK1 and TBK1 play in 
promoting constitutive NF-κB activity in human cancers.  Importantly, GSK-3 
(75,118,119) have been reported to drive constitutive NF-κB activity and cell growth/ 
survival in pancreatic cancer.  Moreover, deregulated TAK1 signaling has been 
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associated with oncogenic KRAS in colorectal cancer (92) and may also be linked to 
constitutive IKK and NF-κB activity and chemoresistance in pancreatic cancer (93).  
Despite the evidence of GSK-3-dependent NF-κB activation in pancreatic cancer, the 
mechanism of regulation and a clear distinction between the role of two isoforms, GSK-
3α and GSK-3β remains elusive. Similarly, though TBK1 has been implicated in lung 
cancer, the effect of TBK1 deletion on KRAS driven lung cancers in situ is 
undetermined.  
The remaining chapters will characterize the requirements of GSK-3 isoforms 
(GSK-3α and GSK-3β), and TAK1 for maintaining constitutive NF-κB activity and cell 
growth/ survival in pancreatic cancer cells.   Furthermore, I will investigate the potential 
link between these signaling components, and propose that constitutive canonical and 
non-canonical NF-κB activity is driven by a unique GSK-3α- signaling cascade.  
Collectively, these studies emphasize the significance of NF-κB signaling in pancreatic 
cancer, and highlight the potential of GSK-3α and TAK1 as novel therapeutic targets for 
this disease.   
Finally, I will the first true TBK1 conditional knockout mouse and use it to investigate 
and propose the negative effect of TBK1 inhibition on the development of lung 
adenocarcinomas in mice.  
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FIGURES 
 
Figure 1.1 RAS signaling in an active GTP bound state, RAS interacts with several 
families of effector protein. RAS activate Raf protein kinase that initiate MAP kinase 
cascade which leads to ERK activation. ERK has numerous substrate like ELK1 that 
regulate cell cycle progression. RAS also activates PI3Ks which activate numerous target 
protein including cell survival signaling kinase. PI3K also activates the Rac-Rho 
pathway. Another pathway is RAS related protein, which activates the cell cycle 
progression. Phospholipase Cε is activated by RAS which leads to activation of Ca 
signalling pathway. Adapted from Downward J, Targeting Ras signaling pathways in 
cancer therapy, Nature Reviews (3) 2003:11-22 
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Figure 1.2 Oncogenic mutations of RAS: The key oncogenic mutations are in the 
region that is identical among the 3 isoforms. Of the forty-four separate point mutations 
characterized for RAS isoforms, 99.2% occur at codons 12, 13 and 61. (2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With the exception of the salivary gland, screening has
focused on the locations and isoforms with the strongest
coupling. Of note, however, the mutation rate in the pancreas
is 60% rather than the generally quoted 90%. In most cases, 1
isoform dominates the number of mutations scored for a
particular cancer. One exception is thyroid cancer, in which
large numbers of mutants of all 3 isoforms have been counted.
Although these observations conﬁrm known trends, a com-
parison of codon mutations among the Ras isoforms reveals
some intriguing deeper patterns.
Codon speciﬁcity of Ras isoform mutations
In analogy to the isoform bias we can see in speciﬁc
cancers, analyses of codon mutation frequencies reveal that
each isoform has a distinctive codon mutation signature
(Fig. 2). K-Ras and N-Ras represent 2 extremes of this
phenomenon: 80% of K-Ras mutations occur at codon 12,
whereas very few mutations are observed at codon 61. In
contrast, almost 60% of N-Ras tumors harbor mutations at
codon 61, compared with 35% at codon 12. H-Ras displays an
intermediate behavior, with an approximately 50%/40% split
between mutations at codons 12 and 61, respectively. These
data represent averages of the percentages for each cancer in
which at least 20 tumors were scored. Of importance, a
closer examination of trends within different cancers con-
ﬁrms the individuality of each isoform even in circum-
stances in which the isoforms presumably have been
exposed to common mutagenic factors (Fig. 2B).
These differences in codon speciﬁcity are surprising because
all 3 oncogenic mutations are in amino-acid regions that are
identical among the 3 isoforms and are assumed to generate
equivalent effects on protein activity. Of note, even at the DNA
level, K-Ras and N-Ras share identical sequences encoding
Gly12 and Gln61. Furthermore, individual single-base substi-
tutions result in the same amino-acid replacement for all of the
isoforms. Nevertheless, an examination of the preferred single-
base substitutions collated from all Ras-mutated tumors in the
COSMIC database reveals a ﬁnal level of difference among the
isoforms (Table 2).
Ras codons 12, 13, and 61 can each be converted to 6 other
amino acids via single-base substitutions. However, >60% of
the total mutations for each isoform are accounted for
by only 3 of the 18 potential mutations across the codons
(Table 2). K-Ras mutation patterns are dominated by the
43% of mutations that are G!A transitions at the second
base of codons 12 or 13, resulting in G12D or G13D muta-
tions. G!T transversions at the second base make up the
bulk of the remainder to produce G12V. A special case is
observed in lung cancer, where a G!T transversion of the
ﬁrst base of codon 12 to produce G12C predominates. N-Ras
favors similar types of mutations at codons 12 and 13, albeit
at much lower rates compared with K-Ras. In contrast,
H-Ras favors G12V in all cancers with codon 12 mutations,
and more generally exhibits a 3-fold higher proportion of
transversion-to-transition mutations compared with K-Ras
and N-Ras. Mutations at codon 61 recapitulate the hetero-
geneity that is evident between isoforms at codon 12.
These data reveal that Ras isoforms exhibit differential and
preferential coupling to speciﬁc cancers, codons, and base
substitutions. The distinct mutation patterns exhibited by Ras
Figure 1. Oncogenicmutations of Ras isoforms. The key oncogenicmutations are in the region that is identical among the 3 isoforms. Forty-four separate point
mutations have been characterized inRas isoforms,with 99.2%of all mutations occurring at codons 12, 13, and61.Mutations that cluster in and around loops
1, 2, and4 are responsible for nucleotide binding and result in enhancedGTPbinding. Residues that aremutated in cancer are highlighted in red, those that are
mutated in developmental disorders are underlined, and those that are variable among isoforms are in gray (26, 65, 66).
Prior et al.
Cancer Res; 72(10) May 15, 2012 Cancer Research2458
 American Association for Cancer Research Copyright © 2012 
 on May 17, 2012cancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/0008-5472.CAN-11-2612
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Figure 1.3.  Accumulation of genetic mutations during pancreatic carcinogenesis.  
Pancreatic cancer progression is characterized by three stages of pancreatic intraepithelial 
neoplasia (PanIN-1A/B, PanIN-2, and PanIN-3) followed by invasive pancreatic ductal 
adenocarcinoma (PDA).  The above “PanINgram” illustrates increasing degree of 
cytoplasmic and nuclei atypia used to classify each PanIN lesion (Maitra, Adsay et al. 
2003).  As indicated, genetic alterations in onocogenes (K-RAS and Her2/ Neu) and 
tumor suppressors (p16, p53, DPC4, and BRCA2) arise during distinct stages during 
PanIN progression.  (Adapted from Wilson, W, The Regulation of constitutive NF-κB 
activity by GSK-3 in pancreatic cancer cells, 2008) Adapted with permission. 
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Figure 1.4.  Domain organization of NF-κB family members.  The evolutionarily 
conserved NF-κB family members indicated above exists as homo- or heterodimers.  The 
N-terminal rel homology domain (RHD) mediates DNA binding and coupling with NF-
κB family members.  NF-κB transcriptional activity is facilitated by the C-terminal 
transactivational domain (TAD).  The phosphorylation of p65 at the indicated sites has 
been shown to promote transcriptional activity.  p100 and p105 exist as precursors 
consisting of an inhibitory ankyrin repeat domain which masks nuclear localization 
sequence within the RHD of p65, RelB, and c-Rel.  Upon phosphorylation, p100 and 
p105 undergo proteolytic cleavage giving rise to mature p52 and p50 respectively. 
(Adapted from Wilson, W, The Regulation of constitutive NF-κB activity by GSK-3 in 
pancreatic cancer cells, 2008) Adapted with permission. 
 
 27 
 
 
Figure 1.5.  Canonical versus non-canonical NF-κB signal transduction.  (Left) 
Canonical NF-κB signaling can be triggered by the indicated stimuli which converge on 
the activation of the IKK complex (IKKα, IKKβ, and IKKγ).  Upon activation, IKK 
phosphorylates NF-κB-bound, IκBα at serines 32/ 36.  Consequently, IκBα undergoes 
rapid ubiquitination and subsequent proteosomal degradation.  Liberated NF-κB can 
undergo nuclear translocation and activate target gene expression.  (Right)  Non-
canonical NF-κB signaling can be initiated by the indicated stimuli which activate 
downstream NIK and subsequent IKKα homodimers. IKKα phosphorylates p100/ RelB 
heterodimers at serines 866/ 872.  As a result, p100 undergoes proteolytic cleavage 
giving rise to an active p52/ RelB heterodimer. 
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Figure 1.6.  Domain organization of TAK1 and TAB proteins.  TAK1 consists of an 
N-terminal kinase domain which undergoes autophosphorylation at the indicated serine/ 
threonine residues upon activation.  TAK1 exist in complex with TAK1-binding proteins 
(TAB1, TAB2, TAB3).  TAB1 interacts with N-terminal region of TAK1, while TAB2/3 
interacts at the C-terminal region.  TAB1 consists of an uncharacterized, N-terminal 
protein phosphatase 2C (PP2C) domain.  TAB2/3 contains CUE and zinc-finger domains 
which facilitates interaction with polyubiquitin chains. (Adapted from Wilson, W, The 
Regulation of constitutive NF-κB activity by GSK-3 in pancreatic cancer cells, 2008) 
Adapted with permission. 
 
 
 
 
 
Figure 1.7.  Glycogen synthase kinase-3 isoforms. Glycogen synthase kinase-3 exist a 
two, closely related mammalian isoforms (GSK-3α and GSK-3β).  Gly-Rich indicates the 
N-terminal glycine-rich region located in GSK-3α. GSK-3 activity is mediated by 
autophosphorylation within the kinase domain at tyrosine residues 279 and 216 in GSK-
3α and GSK-3β respectively.  GSK-3 activity undergoes inhibitory phosphorylation at N-
terminal serine residues 21 and 9 in GSK-3α and GSK-3β respectively.  .  (Adapted from 
Wilson, W, The Regulation of constitutive NF-κB activity by GSK-3 in pancreatic cancer 
cells, 2008) Adapted with permission. 
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Figure 1.8.  GSK-3 regulatory pathways and substrate targets.  GSK-3 can be 
negatively regulated by a variety of upstream signaling events through the 
phosphorylation at serines 9 and 21 in GSK-3β and GSK-3α respectively. GSK-3 
phosphorylates serine/ threonine residues in substrates that encompass the indicated 
substrate motif.  Select substrates require a priming phosphorylation event by a secondary 
kinase to enhance GSK-3 substrate phosphorylation.  The various substrates recognized 
by GSK-3 are indicated above.  (Adapted from Wilson, W, The Regulation of 
constitutive NF-κB activity by GSK-3 in pancreatic cancer cells, 2008) Adapted with 
permission. 
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Figure 1.9. TBK1 domain organization The major domains of each TBK1 are depicted 
with amino-acid numbers that correspond to the human proteins. Somatic mutations of 
TBK1 identified in lung adenocarcinomas are marked in red. ULD, Ubiquitin-like 
domain; LZ, leucine zipper; HLH, helix-loop-helix; NBD, NEMO-binding domain 
(adapted from Shen, RR and Hahn, WC Oncogene, 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Figure 1). Despite their similarity in structure, TBK1
and IKKe exhibit differential expression patterns.
TBK1, like IKKa and IKKb, is ubiquitously expressed
(Shimada et al., 1999). In contrast, IKKe expression is
restricted to particular tissue compartments, with high-
est levels detected in lymphoid tissues, peripheral blood
lymphocytes and the pancreas (Shimada et al., 1999).
Various epithelial-derived cell lines also exhibit IKKe
expression (Shimada et al., 1999; Gravel and Servant,
2005; Honda et al., 2005; Bibeau-Poirier et al., 2006).
Mitogenic stimulation with LPS and TNFa can also
induce IKKe and TBK1 expression in a NF-kB
dependent manner (Shimada et al., 1999; Kravchenko
et al., 2003; Hemmi et al., 2004). With these partially
overlapping characteristics, IKKe and TBK1 are func-
tionally more similar to each other than the canonical
IKKs (Clement et al., 2008).
The non-canonical IKKs coordinate the interferon
response
IKKe and TBK1 are critical inducers of interferon
signaling in response to viral infection (Fitzgerald et al.,
2003; Sharma et al., 2003). Following activation of toll-
like receptors by viral components, IKKe and TBK1
assemble with TRAF3 and TANK to phosphorylate
interferon regulatory factors (IRFs) 3, 5 and 7 at
multiple serine and threonine residues (Pomerantz and
Baltimore, 1999; McWhirter et al., 2004; Mori et al.,
2004; Caillaud et al., 2005; Cheng et al., 2006). This
activity allows for heterodimerization and nuclear
translocation of the IRFs and induction of pro-
inflammatory and antiviral genes, including IFN-a/b
(Lin et al., 1998; Sato et al., 2000). Toll-like receptor-
independent mechanisms also activate IKKe and TBK1
to induce the interferon response. In this scenario, viral
double stranded RNA and DNA initiate signaling
through intracellular RNA and DNA sensors such as
RIG-I, MDA-5 and DAI (Andrejeva et al., 2004;
Yoneyama et al., 2004; Kawai et al., 2005; Meylan
et al., 2005; Seth et al., 2005; Takaoka et al., 2007).
IFNb also activates a toll-like receptor-independent
pathway by stimulating IKKe phosphorylation of
STAT1 to facilitate binding with ISGF3, a complex
that serves as the transcriptional machinery important
for activating a subset of interferon response genes
(Tenoever et al., 2007). Moreover, engagement of
both toll-like receptor-dependent and -independent
pathways recruits additional scaffolding molecules
including FADD, TRADD, MAVS, NAP1, HSP90
and SINTBAD which are necessary for IKKe
and TBK1-mediated interferon activation (Rothe
et al., 1996; Balachandran et al., 2004; Hacker et al.,
2006; Oganesyan et al., 2006; Yang et al., 2006; Gatot
et al., 2007; Guo and Cheng, 2007; Ryzhakov and
Randow, 2007; Michallet et al., 2008). Thus, IKKe and
TBK1 form several protein complexes, the composition
of which is dependent on the type of cellular stimuli.
Ultimately, these signaling complexes share a role in
activating interferon responses for achieving an antiviral
state.
The ability of IKKe and TBK1 to activate the
interferon response is also dependent on post transla-
tional modifications by proteasome-independent Lys-63
linked ubiquitin chains (Figure 2). Both IKKe and
TBK1 have an ubiquitin like domain, and Lys-63
ubiquitination of both kinases are promoted by TRAF3,
which itself is Lys-63 ubiquitinated. Disruption of this
activity by TAXBP1 and the deubiquitinase A20 ablates
the interferon response (Ikeda et al., 2007; Parvatiyar
et al., 2010). Both TBK1 and IKKe also mediate
ubiquitination of TANK by an unknown E3 ligase
(Gatot et al., 2007). Although TANK further serves as a
phosphorylation target of TBK1 and IKKe, TANK
ubiquitination seems to occur independently of this
kinase activity. The mechanism by which TANK
ubiquitination contributes to the activation of IKKe
and TBK1 is unknown. Lys-63 ubiquitination also has a
role in the negative regulation of IKKe and TBK1
induced responses. For example, during- by RNA
viruses, Lys-63 ubiquitination of MAVS is essential for
the recruitment of IKKe and leads to the inhibition of
antiviral and NF-kB induced inflammatory genes (Paz
et al., 2009). Ultimately, these modifications will likely
dictate a dynamic system of regulating IKKe and
TBK1-mediated function in both inflammation and
cancer.
The non-canonical IKKs function as NF-kB effectors
Although TBK1 and IKKe are not a part of the classical
IKKa/b/g signaling complex, these kinases were origin-
ally characterized as activators of NF-kB and target
multiple NF-kB members and effectors. Both IKK-
related kinases phosphorylate IkBa at, one of the two-
serine residues typically targeted on IkBa. Although
IKKe phosphorylates Ser36, TBK1 phosphorylates Ser32
IKKε LZ HLH 7161 ULDKinase domain
TBK1
IKKβ HLHKinase domain NBD
15 300 458 486 737 742
7561 LZULD
311 388 603 642
IKKα HLHLZKinase domain NBD
15 301 599 638
7451
455 483 738 743
LZKinase domain 7301 ULD
305 383 591 632
HLH
578 619350 383 W445S
9 300 500 527G417D
9 300 499 527 P675L
Figure 1 Structural comparison of the classical and non-canonical
IKKs. The major domains of each IKK kinase are depicted with
amino-acid numbers that correspond to the human proteins. The
kinase domain of IKKe exhibits 27% and 24% identity to IKKa
and IKKb, resp ctively, and TBK1 shares 49% identity and 65%
similarity to IKKe. Som tic mutations of IKKe and TBK1 recently
identified in lung adenocarcinomas are marked in red. ULD,
Ubiquitin-like domain; LZ, leucine zipper; HLH, helix-loop-helix;
NBD, NEMO-binding domain (May et al., 2004; Hiscott et al.,
2006; Perkins, 2007; Kan et al., 2010).
Roles for the non-canonical IKKs in cancer
RR Shen and WC Hahn
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Table 1.1 Frequency of genetic mutations associated with pancreatic cancer. 
(Adapted from Wilson, W, The Regulation of constitutive NF-κB activity by GSK-3 in 
pancreatic cancer cells, 2008) Adapted with permission 
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Table 1.2 Genetic abnormalities in specific lung cancers 
(Adapted from Herbst, R et al., Lung Cancer, The New England Journal of Medicine, 
2008) 
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Clonal Evolution
Changes in certain genes (e.g., proinflammatory 
interleukin-8 [IL8] and some DNA-repair genes) 
occur in nonmalignant lung tissue of smokers 
and patients with lung cancer, a finding consis-
tent with diffuse tissue injury.3,27-29 These chang-
es probably precede epithelial clonal evolution, an 
important element of the molecular origins of 
lung and other cancers (Fig. 1). Patches of clon-
ally related cells, or clonal patches containing 
40,000 to 360,000 cells, have been mapped in the 
lung.30 The size and number of subclones in a 
clonal patch may contribute to the cancer risk.31 
Early events in the development of non–small-
cell lung cancer include loss of heterozygosity at 
chromosomal region 3p21.3 (site of RASSF1A, a 
member of the Ras association domain family, 
and FUS1), 3p14.2 (FHIT, a fragile histidine triad 
Table 1. Genetic Abnormalities Specific in the Lung to Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer.*
Abnormality Non–Small-Cell Lung Cancer Small-Cell Lung Cancer
Squamous-Cell 
Carcinoma Adenocarcinoma
Precursor
Lesion Known (dysplasia) Probable (atypical adenomatous hyperplasia) Possible (neuroendocrine field)†
Genetic change p53 mutation KRAS mutation (atypical adenomatous hyperplasia 
in smokers), EGFR kinase domain mutation  
(in nonsmokers)
Overexpression of c-MET
Cancer
KRAS mutation Very rare 10 to 30%‡ Very rare
BRAF mutation 3% 2% Very rare
EGFR
Kinase domain mutation Very rare 10 to 40%‡ Very rare
Amplification§ 30% 15% Very rare
Variant III mutation 5%¶ Very rare Very rare
HER2
Kinase domain mutation Very rare 4% Very rare
Amplification 2% 6% Not known
ALK fusion∥ Very rare 7% Not known
MET
Mutation 12% 14% 13%
Amplification 21% 20% Not known
TITF-1 amplification 15% 15% Very rare
p53 mutation 60 to 70% 50 to 70%‡ 75%
LKB1 mutation 19% 34% Very rare
PIK3CA
Mutation 2% 2% Very rare
Amplification 33% 6% 4%
* Non–small-cell lung cancer includes squamous-cell carcinoma and adenocarcinoma.
† Neuroendocrine fields have been detected only in tissue surrounding tumors and have been characterized by extremely high rates of allelic 
loss and by c-MET overexpression (Salgia R: personal communication).
‡ Variations are based in part on smoking profiles.
§ The percentages include increased gene copy numbers from amplification or polysomy and represent percentages from resected cancers. 
The percentages are higher in primary tumors from patients with metastatic disease. Increased copy numbers have been reported in 
squamous dysplastic lesions but not in adenocarcinoma precursors.
¶ Genomic EGFR variant III mutations have been detected only in lung squamous-cell carcinoma, and these tumors are sensitive preclinically 
to irreversible EGFR tyrosine kinase inhibitors. The incidence of 5% is substantially lower than that of 30 to 40% for the detection in 
squamous-cell carcinoma or adenocarcinoma by immunohistochemical analysis or other techniques.
∥ The anaplastic lymphoma kinase (ALK) fusion gene (involving chromosome 2p), consisting of parts of EML4 and ALK, is transforming in 
 fibroblasts and occurs in adenocarcinoma but not in other types of non–small-cell lung cancer or other nonlung cancers.
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CHAPTER II1  
GSK-3α PROMOTES ONCOGENIC KRAS FUNCTION IN PANCREATIC CANCER 
VIA TAK1-TAB STABILIZATION AND REGULATION OF NON-CANONICAL NF-
κB 
2.1 Summary 
 
Mutations in KRAS drive the oncogenic phenotype in a variety of tumors of 
epithelial origin.   The NF-κB transcription factor pathway is important for oncogenic 
RAS to transform cells and to drive tumorigenesis in animal models.   Recently TAK1, 
an upstream regulator of IKK, which controls canonical NF-κB, was shown to be 
important for chemoresistance in pancreatic cancer and for regulating KRAS+ colorectal 
cancer cell growth and survival.  Here we show that KRAS+ upregulates GSK-3α leading 
to its interaction with TAK1 to stabilize the TAK1/TAB complex to promote IKK 
activity.   Additionally, GSK-3α is required for promoting critical non-canonical NF-κB 
signaling in pancreatic cancer cells. Pharmacologic inhibition of GSK-3 suppresses 
growth of human pancreatic tumor explants, consistent with the loss of expression of 
oncogenic genes such as c-myc and TERT.  These data identify GSK-3α as a key 
downstream effector of oncogenic KRAS via its ability to coordinately regulate distinct 
NF-κB signaling pathways.  
                                                
1 This chapter has been adapted from: Bang, D et al. GSK-3α Promotes Oncogenic 
KRAS Function in Pancreatic Cancer via TAK1-TAB Stabilization and Regulation of 
Non-Canonical NF-κB.  Cancer Discovery 2013. 3: 690-703. 
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2.2 Introduction 
 
Numerous epithelial-derived cancers express mutated/activated KRAS, and many of 
these cancers depend upon KRAS-induced signaling for regulation of growth, survival 
and metabolism (1,26).  For example, the great majority of pancreatic ductal 
adenocarcinomas (PDAC) exhibit mutations in KRAS. However, specific targeting of 
mutant oncogenic KRAS has been a therapeutic challenge (87,88). Thus, targeting 
downstream effectors has emerged as an alternative approach to inhibiting oncogenic 
KRAS functions.    Examples of downstream signaling proteins that are important in 
KRAS-dependent growth and survival are the kinases TAK1 and GSK-3, in the context 
of colorectal (TAK1) and pancreatic cancers (TAK1, GSK-3) (68,69) (89).  Interestingly, 
TAK1 and GSK-3 have roles in promoting the activity of components of the NF-κB 
transcription factor family, which is known to be important for KRAS-driven 
oncogenesis.   
 
NF-κB represents a family of evolutionary conserved transcription factors consisting 
of RelA (p65), c-Rel, RelB, p50 (precursor p105) or p52 (precursor p100) subunits 
(44,90-92). Dimers of these subunits regulate transcription of genes associated with 
inflammation, proliferation, and regulation of cell death. NF-κB complexes are inhibited 
through interaction with IκB proteins. Two distinct pathways have been characterized 
that lead to activation of NF-κB. The first, and most intensively studied, is the canonical 
NF-κB pathway defined by activation of the p65-p50 dimer.  This pathway is dependent 
upon the activation of the IκB kinase complex (IKK) which consists of two catalytic 
subunits (IKKα and IKKβ) and a regulatory subunit (IKKγ) (90). The activated IKK 
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complex phosphorylates IκB leading to its ubiquitination and subsequent proteasome-
dependent degradation, allowing NF-κB to accumulate in the nucleus and facilitate 
transcription of target genes. The second is the non-canonical NF-κB signaling pathway, 
which is dependent upon activation of NIK (NF-κB inducing kinase).  Activated NIK 
leads to activation of IKKα homodimers, which phosphorylate p100, leading to its 
proteolytic processing and generation of the active p52 subunit. Consequently RelB-p52 
heterodimers accumulate in the nucleus to drive transcription of target genes (93). 
 
NF-κB activity has been linked to the progression of multiple human cancers where it 
suppresses cell death and promotes cell proliferation, angiogenesis and invasion (44,91).  
We initially showed the importance of NF-κB in RAS-induced cell transformation (51). 
We and others have confirmed this in animal models of RAS-driven cancer (3,41,42,94).  
Consistent with this, NF-κB is constitutively active in the great majority of pancreatic 
cancer cell lines and tumors (95). Previous work has demonstrated that constitutive NF-
κB activity is dependent upon IKK in pancreatic cancer cell lines (55-58) and knockout 
of IKKβ suppresses tumor growth/progression in a KRAS/INK4a null animal model of 
pancreatic cancer (61). Moscat and colleagues showed the importance of p62 in 
coordinating TRAF6 to regulate IKK downstream of oncogenic KRAS-induced signaling 
(54). Elucidating additional signaling components in the canonical NF-κB pathway as 
well as understanding events associated with non-canonical NF-κB activation induced by 
KRAS is important in understanding KRAS-induced transformation. 
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Transforming growth factor-beta activated kinase 1(TAK1) is a mitogen activated 
protein kinase kinase kinase (MAP3K) that initiates downstream NF-κB and MAPK 
signaling in response to cytokines (63). TAK1 activity is dependent upon its association 
with TAK1-binding partners (TAB1, TAB2, TAB3 and TAB4) which facilitate auto-
phosphorylation of TAK1 (Thr178, Thr184, Ser192) within the kinase activation loop. 
(64,96). Upon activation, TAK1 promotes the activity of p38 and JNK MAPKs (97). 
TAK1 plays a central role in NF-κB activation through direct phosphorylation of IKKβ 
(63).  As described above (68,69), TAK1 has been shown to be important for survival of 
KRAS-dependent colorectal cancers and to play an important role in the chemoresistance 
of pancreatic cancers. 
 
GSK-3 is a multifunctional serine/threonine kinase that exists as closely related 
isoforms (GSK-3α and GSK-3β) (72). It is a key enzyme involved in diverse biological 
processes such as cell cycle progression, differentiation and apoptosis (98). Moreover, 
GSK-3 has been implicated in as playing an oncogenic role in various human 
malignancies including pancreatic cancer (76,78,98). While most studies have focused on 
GSK-3β and its involvement in regulating the WNT/β-catenin pathway, a recent study 
implicated GSK-3α in promoting AML (80). We and others have demonstrated that 
GSK-3 regulates growth and survival in pancreatic cancer cell lines by driving 
constitutive IKK and subsequent NF-κB DNA binding and activity (57,79). However, the 
mechanism of how GSK-3 activates IKK and a clear distinction, if any, between the roles 
of the two isoforms GSK-3α and GSK-3β remains elusive. 
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Here we investigate the roles of GSK-3α, GSK-3β, and TAK1 downstream of mutant 
KRAS in driving constitutive NF-κB signaling, proliferation and survival in pancreatic 
cancer cells. We establish a regulatory link between GSK-3α and TAK1 and propose that 
constitutive canonical NF-κB activity is driven by a unique GSK-3α-TAK1-IKK 
signaling cascade. We also provide evidence that GSK-3α regulates non-canonical NF-
κB activity in pancreatic cancer cells, independent of GSK-3β, which contributes to 
growth/survival of pancreatic cancer cells. Moreover, we show that acute inhibition of 
GSK-3 in human pancreatic tumor explants suppresses tumor growth and identify a 
comprehensive transcriptional profile that is changed upon GSK-3 inhibition.  
Collectively, these data provide new insight into constitutive NF-κB regulation in 
oncogenic KRAS-induced pancreatic cancer, and establish GSK-3α and TAK1 as 
potential therapeutic targets for this disease. 
2.3 Results 
2.3.1 GSK-3α/β  promote proliferation/survival of pancreatic cancer cells.  
Consistent with previous reports (57,78), we observed a decrease in proliferation of 
two well characterized KRAS+ pancreatic cancer cell lines, Panc-1 and MiaPaCa-2, upon 
treatment with the selective GSK-3 inhibitor, AR-A014418 in a dose dependent manner 
(Fig. 1A, Supplementary S1). To exclude potential off-target effects of the drug and to 
determine the individual requirements for GSK-3α and GSK-3β for cell 
survival/proliferation, RNA interference was utilized to knock-down individual isoforms. 
Significant reduction in the cell index of MiaPaCa-2 cells was observed following GSK-
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3α RNA interference as compared with non-targeting control and GSK-3β siRNA or both 
GSK-3α/β siRNA (Fig. 1B).  
 
To further explore the effects of GSK-3 inhibition on pancreatic cancer cell function, 
we analyzed the effect of GSK-3α/β knockdown on the colony formation of pancreatic 
cancer cells in soft agar. GSK-3α RNA interference inhibited soft agar growth of 
MiaPaCa-2 cells significantly as compared to non-targeting control or GSK-3β siRNA 
(Fig. 1C). Importantly the size of the colonies formed by GSK-3α depleted cells was 
significantly smaller than that of control or GSK-3β depleted cells.  To determine if this 
abrogated soft agar growth correlated with induction of apoptosis, we measured PARP 
cleavage after the knockdown of GSK-3α and GKS-3β.  Depletion of either GSK-3α or 
GSK-3β led to a modest increase in PARP cleavage (Supplementary S1 and see below). 
 
Consistent with previous reports (57,78), GSK-3 inhibition suppressed 
phosphorylation of IKK and of RelA/p65 (Fig. 1D), markers of canonical NF-κB 
signaling. Interestingly GSK-3 inhibition also decreased the levels of TAK1, upstream 
IKK kinase (63). This led us to hypothesize and investigate a link between GSK-3 and 
TAK1 in regulating NF-κB activity in pancreatic cancer cells. 
 
2.3.2 Oncogenic KRAS promotes TAK1-TAB interaction to drive canonical NF-κB 
activity.   
The activity of TAK1 is dependent upon its association with TAK-1 binding 
proteins (TAB1, TAB2, TAB3) (64). To determine whether TAK1 is active in pancreatic 
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cancer cell lines, we examined the status of TAK1- TAB1 binding in pancreatic cancer 
cells and questioned if mutant KRAS affects TAK1-TAB1 interaction.  TAK1-TAB1 
interaction was analyzed by immunoprecipitating TAK1 from an immortalized, human 
pancreatic ductal epithelial cell line (HPDE6), and in the derivative KRASG12V-
transformed HPDE6 cells (HPDEKR+) and from MiaPaCa-2 cells.  Relative to KRAS+ 
MiaPaCa-2 cells and HPDE6KR+ cells, a significant (34%) decrease in TAK1-TAB1 
binding was found in HPDE cells (Fig. 2A) indicating that mutant KRAS promotes 
TAK1-TAB1 interaction. Consistent with this hypothesis, knockdown of KRAS in 
HPDEKR+ cells strongly reduced TAK1 protein levels and TAK1-TAB interaction in 
HPDEKR+ cells. (Supplementary S2). These data demonstrate that mutant KRAS drives 
constitutive TAK1 activity in pancreatic cancer cell lines via stabilizing TAK1. 
 
To determine whether TAK1 activity is required for NF-κB activity in pancreatic 
cancer cells, the effects of transient TAK1 depletion were measured relative to canonical 
NF-κB activity. siRNA mediated TAK1 knockdown resulted in diminished 
phosphorylation of IκBα (Serine 32/36), stabilization of total IκBα levels and reduced 
phosphorylation of p65/RelA, indicating reduced canonical NF-κB activation (Fig. 2B).  
Taken together, our data indicate that TAK1 plays a key role in regulating NF-κB activity 
in pancreatic cancer cells, consistent with the study by Melisi et al (69), and that 
oncogenic KRAS promotes TAK1 activity by promoting TAK1 stabilization and hence 
the TAK1-TAB interaction.  
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To determine the functional significance of TAK1-mediated NF-κB activity, we 
examined the effect of TAK1 depletion on pancreatic cancer cell proliferation/survival. 
siRNA mediated TAK1 depletion significantly reduced the cell index of MiaPaCa-2 cells 
relative to the non-targeting control throughout the time-course in an MTS assay (Fig. 
2C). This reduced cell index correlated with a weak PARP cleavage response 
(Supplementary S1). Importantly, this effect of TAK1 depletion was specific to cells 
harboring mutant KRAS, as knockdown of TAK1 did not decrease cell proliferation in 
HPDE6 cells unlike HPDEKR+ (Fig. 2D).   Notably, the effect of TAK1 depletion on 
cell index was significantly weaker than that seen with pharmacologic inhibition of GSK-
3, possibly because of incomplete knockdown of TAK1.  
 
To achieve a greater inhibition of TAK1 kinase activity, we analyzed the effect of 
a selective and potent TAK1 kinase inhibitor, 5Z-7-oxozaenol, on cell 
survival/proliferation of pancreatic cancer cells (68). Consistent with our hypothesis, 
TAK1 inhibitor treatment resulted in a greater decrease in cell proliferation of MiaPaCa-2 
compared to TAK1 knockdown (Fig. 2E). Again the inhibitory effect of TAK1 inhibitor 
on cell proliferation was specific to mutant KRAS harboring cells. (Supplementary S3). 
The decrease in phosphorylation of p38 (TAK1 substrate) confirms the inhibition of 
TAK1 activity upon 5Z-7-oxozaenol treatment (Supplementary S2).  
 
A modest increase in PARP cleavage upon TAK1 and GSK-3 inhibition 
(Supplementary S2) argues against the induction of apoptosis as a major mechanism 
resulting in reduced cell index. We thus, examined the effect of TAK1 inhibition on cell 
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cycle distribution. Panc-1 cells were treated with 5Z-7-oxozaenol and stained with PI.  
An increase in the number of cells in G2/M phase was observed with increasing 
concentration of the TAK1 inhibitor (Supplementary S4), suggesting that TAK1 
inhibition leads to a G2/M arrest in pancreatic cancer cells leading to decreased 
proliferation. As shown below, the effect of GSK-3 inhibition on cell proliferation may 
be via TAK1 and thus cell cycle deregulation. Overall, these data suggest that TAK1 is 
active downstream of mutant KRAS in pancreatic cancer cells and mediates constitutive 
NF-κB signaling to regulate proliferation by altering cell cycle progression. 
 
2.3.3 GSK-3α facilitates constitutive TAK1 activity by maintaining TAK1-TAB1 
interaction. 
We and others previously demonstrated that GSK-3 drives constitutive IKK and 
NF-κB activity in pancreatic cancer cell lines (57). In Fig. 1C we observed a decrease in 
TAK1 levels with GSK-3 inhibition in Panc-1 and MiaPaCa-2 cells.  To further analyze a 
role for GSK-3 in regulating TAK1-dependent NF-κB signaling, Panc-1 and MiaPaCa-2 
cells were treated with GSK-3 inhibitor over a 24-hour time course.  Results from this 
experiment revealed a time-dependent decrease in levels of TAK1, its binding partners 
TAB1 and TAB2, and NF-κB p65 phosphorylation (Fig. 3A). Though the kinetics of 
decrease in TAK1 and TABs levels were different in Panc-1 and MiaPaCa-2 cells, the 
levels of TAK1 were always consistent with the loss of GSK-3 activity, as seen by 
suppression of phospho-glycogen synthase, a substrate of GSK-3. Moreover, we also saw 
a decrease in TAK1 substrate phosphorylation (phospho-p38) with GSK-3 inhibition 
(Supplementary S5). To determine if the loss in TAK1 protein levels is due to 
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proteasome-dependent degradation, Panc-1 and MiaPaCa-2 cells were treated with AR-
A014418 in the presence of proteasome inhibitor (MG-132).  The results demonstrated 
that MG-132 treatment restored reduced TAK1 levels in Panc-1 cells but not in 
MiaPaCa-2 cells (Supplementary S6).  To demonstrate that the decrease in TAK1 levels 
was not an off-target effect of AR-A01448, siRNA was used to transiently knockdown 
GSK-3α and/or GSK-3β in Panc-1 and MiaPaCa-2 cells. 48 hours after siRNA 
transfection, a decrease in TAK1 levels was observed with knockdown of GSK-3α but 
not of GSK-3β (Fig. 3B).  
 
To further analyze the mechanism of GSK-3-TAK1 regulation, we investigated 
whether GSK-3 isoforms can physically interact with TAK1. Endogenous TAK1 was 
immunoprecipitated from MiaPaCa-2 cells and blotted for GSK-3α and GSK-3β. We 
observed GSK-3α co-precipitating with TAK1 in KRAS transformed pancreatic cancer 
cells (MiaPaCa-2 and HPDE-KR+) as well as non-transformed HPDE (Fig. 3C), although 
the level of interaction was higher in the KRAS+ cells.  Consistent with previous studies 
(99), expression of oncogenic KRAS led to the upregulation of GSK-3 isoforms (Fig. 
3C). Since GSK-3α-TAK1 co-immunoprecipitated in non-transformed HPDE’s as well 
as transformed pancreatic cancer cells, we sought to explore this interaction in other cells 
like 293T cells. These cells have very low levels of GSK-3 and TAK1 as compared to 
pancreatic cell lines, prompting us to overexpress these proteins to detect any interaction. 
Expression of V5-tagged GSK-3α with TAK1 in 293T cells led to an interaction as 
determined by co-immunoprecipitation (Fig. 3D). No interaction between over-expressed 
GSK-3β and TAK1 was observed indicating specificity to GSK-3α (data not shown).  
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To determine if GSK-3 kinase activity is required for maintaining the TAK1-TAB 
interaction (and not just TAK1 and TAB levels), we evaluated the effect of GSK-3 
inhibition on TAK1-TAB1 complex in MiaPaCa-2 cells. Since AR-A014418 treatment 
affects TAK1 levels, we transiently over-expressed TAK1 in MiaPaCa-2 cells, before 
treating the cells with AR-A014418. As is evident in Fig. 3E, GSK-3 inhibition 
suppressed the co-precipitation between TAK1 and TAB1, even under conditions where 
TAK1 and TAB1 levels are maintained. Thus GSK-3 catalytic activity appears to be 
important in maintaining the TAK1-TAB1 complex. Overall, these data and those 
described above demonstrate that mutant KRAS induces TAK1-TAB1 interaction that is 
stabilized by GSK-3α leading to higher TAK1-dependent NF-κB activity in pancreatic 
cancer cells.  
 
2.3.4 GSK-3α facilitates constitutive non-canonical signaling in pancreatic cancer 
cells.   
Non-canonical NF-κB pathway leading to processing of NF-κB2/p100 to p52, has 
been shown to be constitutively active in pancreatic cancer cells (59,60). To this point, 
the data links GSK-3 to constitutive canonical NF-κB signaling via TAK1. However, the 
effect of GSK-3 inhibition on cell survival/proliferation was much greater than that 
observed with depletion of TAK1, suggesting that another component regulated by GSK-
3 affects pancreatic cell survival/proliferation. Thus, we asked if GSK-3 regulates the 
non-canonical arm of NF-κB in pancreatic cancer cells.  Processing of p100 to p52 in 
Panc-1 and MiaPaCa-2 cells was suppressed when these cells were treated with the GSK-
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3 inhibitor, AR-A014418 (Fig. 4A). To account for potential off-target effects of the 
GSK-3 inhibitor, p100-p52 processing was analyzed upon GSK-3α/β depletion by 
siRNA. Depletion of GSK-3α but not GSK-3β led to a decrease in p100-p52 processing 
in Panc-1 and MiaPaCa-2 cells (Fig. 4B), again highlighting differences between GSK-3α 
and GSK-3β.  Upon processing of p100, p52 accumulates in the nucleus to promote 
transcription of its target genes. We examined the effect of GSK-3α knockdown on the 
nuclear localization of p52. Surprisingly we saw that GSK-3α depletion suppressed p52 
levels only in the nuclear fraction and not in the cytoplasmic extract (Fig. 4C). This 
suggests that either GSK-3α promotes nuclear accumulation of p52 or that GSK-3α 
regulates the processing of p100 in the nuclear fraction.  
 
The functional importance of the non-canonical NF-κB pathway was measured 
via the effect of p100 knockdown on the cell index of pancreatic cancer cells. As 
compared to the non-targeting control, p100 knockdown suppressed the cell index of 
Panc-1 cells in a cell impedance assay (Fig. 4D). This suppression of cell index was 
greater than that observed with TAK1 depletion. Knockdown of p100 modestly increased 
PARP cleavage in MiaPaCa-2 but not in Panc-1 cells (Supplementary S7). Overall, these 
data provide a novel link between GSK-3α and the non-canonical NF-κB pathway in 
pancreatic cancer cells. These results may explain why knockdown of GSK-3α (that 
affects both canonical and non-canonical NF-κB) leads to a greater suppression of cell 
growth as compared to knockdown of GSK-3β or TAK1 (Fig. 1 C, D). 
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2.3.5 GSK-3 inhibition suppresses growth of patient-derived pancreatic tumor 
explants.  
Our data and previous reports suggest that GSK-3 inhibition may be a potential target 
for pancreatic cancer treatment because of its effect on NF-κB activity. However, the 
effect of GSK-3 inhibition on human pancreatic tumors has never been evaluated. To 
analyze the effect of GSK-3 inhibition on tumor growth in vivo, we explanted replicates 
of a human pancreatic tumor in nude mice. Two weeks later, GSK-3 inhibitor, AR-
A014418, was administered intraperitoneally at 120 mg/kg twice a day for two days. The 
growth of the tumor was then monitored over a course of 28 days. Consistent with our 
hypothesis and data, GSK-3 inhibition suppressed tumor growth in mice by 
approximately 50% (Fig. 5A). To analyze the effect of acute GSK-3 inhibition on the 
TAK1/NF-κB signaling in mice, we repeated the AR-A014418 treatment study on 
pancreatic tumor explants for shorter time courses (1h, 2h, 6h and 8h). We observed a 
time-dependent decrease in TAK1 and TAB levels in these tumors, consistent with our 
studies in pancreatic cancer cell lines (Fig. 5B).  Overall these data indicate that GSK-3 
inhibition suppresses pancreatic tumor growth with a concomitant decrease in TAK1-
TAB activity.  
 
2.3.6 Effect of GSK-3 inhibition on gene expression in human patient-derived 
pancreatic tumor explants.    
We next sought to determine the effect of GSK-3 inhibition on gene expression in 
the human pancreatic tumor explants in mice.  Gene expression microarrays were utilized 
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to identify global changes in gene expression that occurred in these tumors when treated 
with GSK-3 inhibitor. Supervised gene expression analyses were conducted to quantify 
gene expression changes in the tumors, after 2 or 8 hours of AR-A014418 treatment (Fig. 
6A).  GSK-3 inhibition led to a statistically significant change in expression (based on 
SAM analysis) for 470 genes, of which 155 changed more than 2 fold (Fig. 6A).  We 
further analyzed known or suspected to be NF-κB target genes changed by GSK-3 
inhibition.  In this group, GSK-3 inhibition led to a statistically significant down-
regulation of 17 genes after 8h and 22 genes after 2 hours of treatment (Fig. 6B). 15 out 
of these genes were downregulated more than 1.5 fold, with greater downregulation 
occurring at the 8h time point. As shown in Fig. 6C, most of these genes have been 
shown to have a pro-oncogenic role in pancreatic cancer.  For example, we observe a 
decrease in the expression of pro-proliferative genes like c-Myc, TERT, and cIAP2 with 
GSK-3 inhibition. 
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2.4 Discussion 
 
Mutant KRAS is expressed in virtually all pancreatic cancers as well as in other 
epithelial-derived cancers where it serves as a key oncogenic factor, promoting 
proliferation and survival (1,26). Despite extensive research, less than 4% of patients 
diagnosed with pancreatic cancer are expected to survive past 5 years (100). Since no Ras 
inhibitors have been effective (26,87), current research efforts are focusing on targeting 
deregulated signaling pathways downstream of KRAS+. The advancement of this 
therapeutic strategy is dependent on a detailed understanding of the complex molecular 
mechanisms underlying signaling events that regulate disease progression.  
 
NF-κB is known to be constitutively active in majority of the pancreatic tumors and 
pancreatic cancer cell lines, where it regulates proliferation, survival, metastasis and 
invasion (95). NF-κB has also been shown to be activated downstream of oncogenic Ras 
and promote the oncogenic phenotype (42,94). Thus, the signaling cascades activating 
NF-κB pathway have become attractive targets for novel chemotherapeutic approaches in 
pancreatic and other cancers (95). There is evidence that multiple of arms of NF-κB are 
activated in various cancers (44), thus the ability to block NF-κB activity broadly may 
require multiple inhibitors unless a factor can be identified that regulates multiple NF-κB 
-relevant signaling pathways. 
 
Previous studies from our lab and others have shown that GSK-3 inhibition reduces 
pancreatic cancer cell viability in vitro and suppresses tumor cancer cell line growth in 
vivo at least partly through the downregulation of NF-κB activity (57,78,79,101). 
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However the mechanism by which GSK-3 regulates NF-κB and the distinct roles of the 
two isoforms, GSK-3α and GSK-3β, are not well characterized. In this report, we provide 
the first evidence for a role of GSK-3α in regulating proliferation and anchorage-
independent growth of pancreatic cancer cells independent of GSK-3β. We previously 
reported that GSK-3 signals through IKK to mediate canonical NF-κB signaling in 
pancreatic cancer cells (57). Here, we propose that GSK-3 and IKK are functionally 
linked through GSK-3α-dependent control of TAK1-TAB1 complex stability/activity, 
and provide the first evidence for regulation of non-canonical NF-κB by GSK-3α.  
 
TAK1 is a central regulator of NF-κB signaling in diverse physiological processes 
including development, immune responses and survival (63). Its binding partner, TAB1 
was recently shown to play an essential role in the maintenance of TAK1 activity in 
epithelial tissues (64). Here, we show that the TAK1-TAB1 complex is active in KRAS+ 
cancer cells and is stabilized via a GSK-3α-dependent mechanism (Fig. 2). TAK1 was 
recently identified as a pro-survival mediator in KRAS+-dependent colon cancer (68). 
While Singh et al argue against the pro-survival role of TAK1 in pancreatic cancer cells, 
another group showed that inhibition of TAK1 leads to a proapoptotic phenotype in 
pancreatic cancer cells, by suppressing NF-κB (68,69) Our results supports aspects of 
each of these studies, as we observe a reduction in NF-κB activity and cell proliferation 
with inhibition of TAK1 in pancreatic cancer cells (Fig. 2), however we do not see a 
strong corresponding increase in apoptosis as measured by cleavage of caspase 3 or 
PARP under these conditions (Supplementary S1,S2). However, inhibition of TAK1 
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leads to G2/M arrest in pancreatic cancer cells (Supplementary S4), which presumably 
causes a decrease in cell proliferation.  
 
A mechanism to describe how TAK1 is activated downstream from oncogenic KRAS 
has not been described.  Previously, Moscat and colleagues (54) showed the involvement 
of p62 in regulating TRAF6 ubiquitination downstream of oncogenic KRAS to promote 
IKK activity.  Here, we provide the first evidence of a regulatory link between GSK-3α 
and TAK1. We show that pharmacological inhibition of GSK-3 in pancreatic cancer cells 
leads to a decrease in levels of TAK1 and its binding partners TAB1 and TAB2 (Fig 
3A,B, Supplementary S8). The decrease in TAK1 and TAB levels were detected as early 
as 1h following GSK-3 inhibitor treatment and were maintained at low levels as long as 
GSK-3 activity was inhibited. The in vitro results were reproduced in vivo when human 
pancreatic tumor explants were treated with AR-A014418 (Fig. 5). These results are 
corroborated by siRNA knockdown of GSK-3α in pancreatic cancer cells. The interaction 
between GSK-3α and TAK1 was found in non-transformed HPDE cells, suggesting that 
GSK-3α can interact with TAK1 irrespective of presence or absence of mutant KRAS.  
However, mutant KRAS upregulates the expression of GSK-3 (99) (Supplementary S9), 
which then promotes the stabilization of the active TAK1-TAB1 complex. TAK1 can 
drive IKK-dependent NF-κB signaling leading to increased proliferation of KRAS+ 
transformed cells. The mechanistic link between GSK-3α and TAK1 is unclear since 
there is no consensus substrate motif of GSK-3 (S/T-XXX-S/T) in TAK1.  However, 
Taelman et al have shown that TAB1 and TAB2 contain multiple GSK-3 consensus 
motifs (102). Thus, there is a possibility that GSK-3 phosphorylates TABs to regulate the 
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TAK1-TAB1 complex and thus the stability of TAK1. This hypothesis will be addressed 
in future studies. 
Although we demonstrate that GSK-3 regulates IKK through TAK1, the effect on cell 
proliferation with GSK-3 inhibition is much stronger as compared to TAK1 inhibition. 
These results suggested that additional regulatory events downstream of GSK-3 promote 
pancreatic cancer cell growth/survival.  Non-canonical NF-κB pathway has been shown 
to be constitutively active and to be contributing to proliferation/survival in pancreatic 
cancer cells (59,60). Thus we explored the potential involvement of GSK-3 in regulating 
p100/NF-κB2 processing.  GSK-3 inhibition, or knockdown of GSK-3α (but not GSK-
3β) leads to significantly reduced p100 processing in pancreatic cancer cells (Fig. 4A,B, 
Supplementary S8). Importantly, we demonstrate a significant reduction in cell 
proliferation of pancreatic cancer cells, upon knocking down p100 subunit (Fig. 4D). We 
also saw a decrease in p100 and p52 levels upon TAK1 inhibition, which is consistent 
with p100 being a known transcriptional target of canonical NF-κB (data not shown). 
Interestingly we observed a decrease in nuclear accumulation of p52 subunit upon GSK-
3α knockdown while, the cytoplasmic levels of p100 and p52 remained unchanged (Fig. 
4C). This indicates a distinct effect of GSK-3α on nuclear p52 different from that derived 
via inhibition of TAK1-regulated canonical NF-κB. GSK-3 has been earlier shown to be 
accumulated in the nucleus in pancreatic cancers (79) which raises the potential that the 
GSK-3 effect on non-canonical NF-κB is via processing of nuclear p100.  It is also 
possible that GSK-3α affects the nuclear transport of p52 subunit. We thus hypothesize 
that GSK-3α regulates both canonical and non-canonical NF-κB pathway in pancreatic 
cancer cells. Notably our results on the regulation of p100 processing by GSK-3α are 
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likely not to relate to the recent work demonstrating the role of GSK-3β and Fbxw7α-
mediated degradation of p100 in multiple myeloma (103) as we do not see p100 
accumulation upon GSK-3α knockdown. However, our study does support the pro-
survival role of p100 – p52 processing in a way similar to that described by Sangfelt and 
colleagues (104).  
 
The human tumor explant study demonstrates a 50% inhibition of KRAS-mutant 
tumor growth upon a 2-day treatment with GSK-3 inhibitor (Fig. 5).   This study was 
performed with a commercially available GSK-3 inhibitor, indicating the need for more 
extensive studies on a broader group of pancreatic tumors using a pharmaceutical grade 
inhibitor.  To analyze the effect of GSK-3 inhibition on NF-κB target gene expression, 
we compared the gene expression profile of tumors, before and after treatment with AR-
A014418. We observed a down-regulation of several established NF-κB target genes 
such as c-myc and TERT, which are known to be upregulated in pancreatic cancer (Fig. 
6C). It is noteworthy that we saw a selective effect on NF-κB dependent gene expression. 
These results are consistent with previous studies that GSK-3 and Ras induce only a 
selective arm of the NF-κB pathway (73,105), which is different from the well 
characterized NF-κB regulated downstream of cytokine-induced signaling. NF-κB may 
also be regulated by upstream activators other than GSK-3 in these tumors, thus 
inhibiting GSK-3 alone will not shut down the entire NF-κB signaling.  
Interestingly, significant changes were observed in long non-coding RNAs upon 
GSK-3 inhibition, which are now emerging as key regulators of oncogenesis (106). We 
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understand that GSK-3 plays important roles in other signaling pathways, including Wnt, 
Notch, Hedgehog, which have been implicated in pancreatic cancers (107) and which 
may account for the rest of the observed changes in gene expression. Implications of 
GSK-3 inhibition on the β-catenin stabilization and Wnt pathway needs consideration 
(107), however our encouraging results on tumor growth inhibition and previous studies 
strongly support the therapeutic potential of GSK-3 inhibitors.  
Collectively, this report provides the first evidence of GSK-3α in promoting 
oncogenic RAS function through regulation of TAK1-TAB activity, upstream of IKK and 
canonical NF-κB, and via control of non-canonical NF-κB activity in pancreatic cancer 
cells (Fig.7). Importantly, this data provides evidence for different roles of GSK-3α and 
GSK-3β in regulating NF-κB signaling in pancreatic cancer cells, and highlights the need 
for the development and testing of GSK-3α specific drugs.  
2.5 Materials and Methods 
 
Cell culture and reagents  
Panc-1, MiaPaCa-2 were purchased from American Type Culture Collection and 
used for no longer than 6 months before being replaced. Human pancreatic ductal 
epithelial cell line (HPDE6) and KRAS4BG12V–transfected HPDE (HPDEKR+) were 
generous gifts from Dr. Channing Der (UNC-Chapel Hill) and were maintained in 
keratinocyte serum-free growth medium. All cell culture reagents were obtained from 
Invitrogen (Carlsbad, CA). The following antibodies were purchased from Cell Signaling 
Techonology: phospho-Glycogen synthase (Ser641), Glycogen Synthase phospho-p65 
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(Ser536), p-65, TAB1, TAB2, Histone H3, Cleaved PARP (Asp214), PARP, phospho-p38 
(Thr180/Tyr182), p38; Santa Cruz Biotechnology: GSK-3α/β, TAK1, GAPDH, β-tubulin; 
Millipore: p100/p52 and Sigma Aldrich: Anti-Flag (M2). GSK-3 inhibitor (AR-A014418) 
was purchased from Sigma-Aldrich. TAK1 inhibitor (5Z-7-oxozaenol) was purchased 
from Tocris Bioscience. 
siRNA interference  
The following human siRNA (siGenome SMARTpool) was purchased from 
Dharmacon as a pool of four annealed dsRNA oligonucleotides: MAP3K7 (M-003790-
06), GSK-3α(M-003009-01), GSK-3β (M-003010-03), NF-κB2 (M-003918-02), and 
non-targeting control#3 (D001201-03). Dharmafect transfection reagent 1 was used to 
transfect 100nM siRNA according to manufacturer’s instruction and cells were harvested 
48 or 72 hours after transfection, as stated. 
Western blot analysis  
Cytoplasmic, nuclear and whole cell extracts were prepared as described previously 
(57). Tumor lysates were prepared by homogenizing ~1mm piece of tumor in lysis buffer 
(50mM Tris (pH7.6), 150mM HCL, 2mM EDTA). NP-40 was added at 1% v/v and 
incubated on a rocking platform for 30 minutes in cold room and cellular debris 
precipitated using centrifugation. Protein extracts were quantified by Bradford assay 
(Bio-rad Laboratories) and analyzed by SDS-PAGE (57).  
MTS Assay 
Cells were seeded in a 96-well plate and allowed to incubate for 24 hours. The 
cells were then treated with the indicated concentrations of AR-A014418 for indicated 
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times and cellular proliferation measured using the CellTiter 96 Aqueous solution, in 
accordance to the manufacturer’s protocol (Promega). For siRNA experiments, the cells 
were seeded in the plate 48 hours after siRNA transfection. 
Cell impedance assay/ real time cell analysis (RTCA)  
Background impedance signal was measured with 50µL cell culture medium per 
well of an E-Plate 16. The final volume in a single well was adjusted to 100µL cell 
culture medium by adding additional 50 µL medium containing 1000 cells. For siRNA 
experiments, cells were seeded 48 hours after transfection. For inhibitor studies, 5Z-7-
oxozaenol was added one day after seeding. After plating, impedance was routinely 
recorded in 2-hour intervals using the xCELLigence RTCA MP instrument (Roche).  
Soft Agar assay. 
MiaPaCa-2 cells were transiently transfected with indicated siRNA as above. 48 
hours after transfection, 8000 cells were suspended in a 0.4% bacto-agar/DMEM layer 
(1ml) and plated over a 0.6% bacto-agar/DMEM layer (2ml) in 6-well plates. 0.5ml 
media was added next day and every 3-4 days thereafter for 2 weeks. After one week 
colonies were stained with 0.5ml of MTT (2mg/ml, Sigma Aldrich). Images were 
acquired and colonies counted using ImageJ 1.46 software. 
Microarray analysis  
Total RNA was purified using RNeasy plus RNA isolation kit (Qiagen), reverse-
transcribed, labeled, and hybridized to an Agilent v2 8X60K whole human DNA 
microarray. Microarrays were scanned using an Agilent DNA microarray scanner and 
features were extracted using Agilent Feature Extraction software version 10.7.3.1. Data 
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were uploaded to the University of North Carolina Microarray Database (UMD). Gene 
expression data were extracted from the UMD for each sample as log2 Cy5/Cy3 ratios, 
filtering for probes with Lowess normalized intensity values greater than 10 in both 
channels and for probes with data on greater than 70% of the microarrays. Hierarchical 
clustering analyses was carried out using Gene Cluster 3.0 (108), data were viewed using 
Java TreeView version 1.1.5r2 (109). Expression changes were determined using a linear 
model with terms for treatment time points (110). This model was fit to each probe, and 
genes corresponding to treatment effects with a q-value ≤ 0.05 (111) were considered 
statistically significant. The data are publicly available in Gene Expression Omnibus 
database (accession number GSE42559) 
Tumor explant study  
Tiny fragments (1.5-2mm) of a resected human pancreatic tumor were implanted 
subcutaneously into the flanks of nude mice. Two weeks later, GSK-3 inhibitor, AR-
A014418 or vehicle control, DMSO was given intraperitonealy at 120mg/kg twice a day 
for two days. The growth of the tumor was measured every alternate day for 28 days. For 
shorter treatments, tumor was harvested immediately after the indicated time periods. 
 
 
  
 67 
FIGURES 
  
 
Figure 2.1. GSK-3α and GSK-3β regulate growth and NF-κB activity in pancreatic 
cancer cells. A, MiaPaCa-2 and Panc-1 cells were treated with dimethyl sulfoxide 
(DMSO) or the indicated concentrations of the GSK-3 inhibitor AR-A014418 for 24, 48, 
and 72 hours. Cell proliferation was measured in triplicate at each time point using a 
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colorimetric MTS tetrazolium assay. B, MiaPaCa-2 cells were transiently transfected 
with GSK-3a, GSK-3b, both GSK-3a and GSK-3b, or nontargeting siRNA. Forty-eight 
hours after transfection, cell growth was measured in triplicate at each time point using a 
cell impedance assay. C, MiaPaCa-2 cells were transiently transfected with the indicated 
siRNA as above. Forty-eight hours after transfection, cells were suspended in bacto-agar 
growth medium, and 7 days later, plates were examined for colony formation. The data 
shown are representative of 2 independent experiments, each carried out in triplicate. D, 
Panc-1 and MiaPaCa-2 cells were treated with DMSO or 30 µmol/L of GSK-3 inhibitor 
AR-A014418 for 24 hours. Whole-cell extracts were immunoblotted with specified 
antibodies 
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Figure 2.2 TAK1 is constitutively active and regulates NF-κB activity in pancreatic 
cancer cells. (A) Endogenous TAK1 was immunoprecipitated from whole cell lysates of 
the indicated cell lines and blotted for TAB1.  (B) Panc-1 and MiaPaCa-2 cells were 
transiently transfected with non-targeting or TAK1 siRNA for 48 hours and immunoblot 
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performed using indicated antibodies. (C) MiaPaCa-2 were transfected with siRNA as 
indicated above and cell viability was measured at the indicated times post-transfection. 
Samples were measured in triplicates and normalized to untransfected cells. (D) HPDE6 
and HPDEKR+ cells were transfected with siRNA targeted against TAK1 and cell 
viability measured as above. (E) MiaPaCa-2 cells were treated with DMSO or the TAK1 
inhibitor, 5Z-7-oxozaenol (OZ) and cell impedance measured in triplicate every 2 hours.  
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Figure 2.3. GSK-3 inhibition suppresses TAK1 levels. (A) Indicated cell lines were 
treated with GSK-3 inhibitor (AR-A014418) for indicated time periods and 
immunoblotting performed on whole cell lysates. Data is representative of 3 independent 
experiments.  (B) Panc-1 and MiaPaCa-2 cells were transiently transfected with indicated 
siRNA for 48 hours, whole cell lysates harvested and immunoblotted against indicated 
antibodies. (C) Endogenous TAK1 was immunoprecipitated from the indicated cell lines 
and immunoblotted for GSK-3α and GSK-3β. (D) TAK1 and V5-tagged GSK-3α were 
transiently expressed in 293T cells for 24h. TAK1 was immunoprecipitated and blotted 
for V5. (E) MiaPaCa-2 cells were transiently transfected with TAK1 plasmid. 24h later 
they were treated with AR-A014418 for 24h. TAK1 was immunoprecipitated and blotted 
for TAB1.  
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 Figure 3.   GSK-3 inhibition suppresses TAK1 levels. A, the indicated cell lines were treated with GSK-3 inhibitor AR-A014418 for the indicated time 
periods and immunoblotting conducted on whole-cell lysates. Data are representative of 3 independent experiments. B, Panc-1 and MiaPaCa-2 cells were 
transiently transfected with the indicated siRNAs for 48 hours, whole-cell lysates harvested and immunoblotted against the indicated antibodies. C, 
control. C, endogenous TAK1 was immunoprecipitated from the indicated cell lines and immunoblotted for GSK-3α and GSK-3β. D, TAK1 and V5-tagged 
GSK-3α were transiently expressed in 293T cells for 24 hours. TAK1 was immunoprecipitated and blotted for V5. E, MiaPaCa-2 cells were transiently 
transfected wit  TAK1 plasmid. Twenty-four hours later, cells were treated with AR-A014418 for 24 hours. TAK1 was immunoprecipitated and blotted 
for TAB1. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IgG, immunoglobulin G; IP, immunoprecipitation. 
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(phospho-p38) with GSK-3 inhibition (Supplementary 
Fig.  S5). To determine if the loss in TAK1 protein levels is 
due t  proteasome-dependent degradation, Panc-1 and Mia-
PaCa-2 cells were treated with AR-A014418 in the presence 
of proteasome inhibitor (MG-132). The results showed that 
MG-132 treatment restored reduced TAK1 levels in Panc-1 
cells but not in Mi aCa-2 cells (Supplementa y Fig. S6). To 
show that the decrease in TAK1 levels was not an off-target 
effect of AR-A01448, siRNA was used to transiently knock-
down  GSK-3a and/or  GSK-3b in Panc-1 and MiaPaCa-2 cells. 
Forty-eight hours after siRNA transfection, a decrease in 
TAK1 levels was observed with knockdown of GSK-3α but 
not of GSK-3β ( Fig. 3B ). 
 To further analyze the mechanism of GSK-3-TAK1 regula-
tion, we investigated whether GSK-3 isoforms can physically 
interact with TAK1. Endogenous TAK1 was immunopre-
cipitated from MiaPaCa-2 cells and blotted for GSK-3α and 
GSK-3β. We observed GSK-3α coprecipitating with TAK1 
in KRAS-transformed pancreatic cancer cells (MiaPaCa-2 
and HPDE-KR + ) as well as nontransformed HPDE ( Fig. 3C ), 
although the level of interaction was higher in the KRAS-
mutant cells. Consistent with previous studies ( 35 ), expres-
sion of oncogenic KRAS led to the upregulation of GSK-3 
isoforms ( Fig.  3C ). Because GSK-3α and TAK1 coimmu-
noprecipitated in nontransformed HPDEs as well as trans-
formed pancreatic cancer cells, we sought to explore this 
interaction in other cells such as 293T cells. These cells have 
very low levels of GSK-3 and TAK1 as compared with pan-
creatic cancer cell lines, prompting us to overexpress these 
proteins to detect any interaction. Expression of V5-tagged 
GSK-3α with TAK1 in 293T cells led to an interaction as 
determined by coimmunoprecipitation ( Fig. 3D ). No interac-
tion between overexpressed GSK-3β and TAK1 was observed, 
indicating specifi city to GSK-3α (data not shown). 
 To determine if GSK-3 kinase activity is required for main-
taining the TAK1–TAB interaction (and not just TAK1 and TAB 
levels), we evaluated the effect of GSK-3 inhibition on the TAK1–
TAB1 complex in MiaPaCa-2 cells. Because AR-A014418 treat-
ment affects TAK1 levels, we transiently overexpressed TAK1 in 
MiaPaCa-2 cells before treating the cells with AR-A014418. As 
is evident in  Fig. 3E , GSK-3 inhibition suppressed the coprecipi-
tation between TAK1 and TAB1, even under conditions where 
on June 12, 2013. © 2013 American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from 
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Figure 2.4. GSK-3α regulates the non-canonical NF-κB pathway in pancreatic 
cancer cells. (A) Panc-1 and MiaPaCa-2 cells were treated with DMSO or AR-A014418 
(30µM) for indicated time periods and whole cell lysates immunoblotted with the 
indicated antibodies. (B) MiaPaCa-2 cells were transiently transfected with indicated 
siRNA for 72 hours and whole cell lysates immunoblotted for indicated antibodies. On 
right is quantitation of the western blot. (C) Panc-1 cells were transiently transfected with 
indicated siRNA for 72 hours, nuclear and cytoplasmic fractions harvested and 
immunoblotted for indicated antibodies. (D) Panc-1 cells were transiently transfected 
with indicated siRNA for 48 hours and cell impedance measured as above.  
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Figure 2.5. GSK-3 inhibition suppresses tumor growth in mice. (A) Nude mice were 
explanted with replicates of human pancreatic tumor and two weeks later treated with the 
GSK-3 inhibitor (AR-A014418) at 120mg/kg twice a day for two days (A) or the 
indicated time periods (B). (A). Tumor volume was measured over 28 days and is 
represented as the fold change in tumor volume compared to treatment start. n (vehicle)= 
4, n (treatment) = 5. (lower panel) Representative photograph of mice at the end of 28 
days. (B) Tumors were harvested after indicated time periods and immunoblotted with 
the indicated antibodies. 
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Figure 2.6. GSK-3 inhibition leads to changes in NF-κB target gene expression. Total 
RNA was isolated from human pancreatic tumor explants treated with AR-A014418 for 
2h or 8h and evaluated by microarray. Gene changes that were statistically significant by 
SAM analysis are shown in the heat map (p≤0.01). Color key is for log2 ratio. (B) 
Statistically significant changes in known NF-κB target genes are shown in the heat map 
(p≤0.05). (C) NF-κB target genes that were downregulated >1.5 fold are listed with their 
known function in pancreatic cancer (p≤0.05). 
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 Figure 6.   GSK-3 inhibition leads to changes in NF-κB target gene expression. Total RNA was isolated from human pancreatic tumor explants treated 
with R-A014418 for 2 or 8 hours and evaluated by microarray. A, gene changes that were st tistically signifi cant by SAM analysis are shown in the heat-
map ( P ≤ 0.01). Color key is for log 2 ratio. B, statistically signifi cant changes in known NF-κB target genes are shown in the heatmap ( P ≤ 0.05). C, NF-κB 
target genes that were downregulated more than 1.5-fold are listed with their known function in pancreatic cancer ( P ≤ 0.05). PI3K, phosphoinositide 
3-kinase. 
Genes Status in pancreatic cancer Fold Function
TP53 Mutated in 50%–75% pancreatic
cancer
1.43 Cell growth, apoptosis
MYC Overexpressed 2.22 Cell growth, apoptosis
WT1 Overexpressed 1.92 Cellular development and
survival
HIF-1α Overexpressed 1.5 Adaptive response to hypoxia
Regulators
of apoptosis
BIRC2
(cIAP2)
High expression associated with
shorter survival 2 Inhibitor of apoptosis
Cytokines/
Chemokines
TNFSF10 Pancreatic cancer resistant to Trail 1.9 Proapoptotic
IL-9 NF-κB dependent transactivation 2 Antiapoptotic
IFN-γ Expressed 1.5 Innate and adaptive immunity
Enzymes
Growth
factors,
ligands, and
modulators
TERT Highly expressed 1.36 Antiapoptotic
HMOX1 Inhibition sensitizes to
chemotherapy 1.7 Heme metabolism, O2 sensor
CYP19A1 Variants associated with KRAStumors 2.8
Aromatase, biosynthesis of
estrogen
KITLG Regulates growth in normalpancreas 1.3 Stem cell factor
Immunoreceptor FCGRT 1.4 Receptor for Fc regions of IgG
Miscellaneous EDN1 Mediates ischemia in acutepancreatitis 2.8 Vasoconstrictor peptide
OPRM1 1.5 GPCR. Activates MAPK, PI3K,NF-κB, PKC
B
A CDMSO 2 h
AR
Txn factors
and their
modulators
8 h
DMSO
CYP19A1
IL9
OPRM1
BIRC2
WT1
MYC
EDN1
HIF1A
TERT
FCGRT
HMOX1
TP53
IL10
IFNG
KITLG
TNFSF10
IL27
EBI3
PTGIS
INHBA
ICAM1
BAX
IGFBP2
NFKBIA
–2.00
–1.33
–0.67
0.00
0.67
1.33
2.00
GSTP1
FAS
NOS2
BCL2L1
MX1
BCL2
SLC6A6
CXCL13
ALOX5
MTHFR
2 h
AR
8 h
analysis] for 470 genes, of which 155 changed more than 2-fold 
( Fig. 6A ). We further analyzed known or suspected NF-κB target 
genes changed by GSK-3 inhibition. In this group, GSK-3 inhibi-
tion led to a statistically signifi cant downregulation of 17 genes 
after 8 hours and 22 genes after 2 hours of treatment ( Fig. 6B ). 
Fifteen of these genes were downregulated more than 1.5-fold, 
with greater downregulation occurring at the 8-hour time point. 
As shown in  Fig. 6C , most of these genes have been shown to 
have a pro-oncogenic role in pancreatic cancer. For example, we 
observed a decrease in the expression of proproliferative genes 
such as  c-Myc ,  TERT , and  cIAP2 with GSK-3 inhibition. 
 DISCUSSION 
 Mutant KRAS is expressed in virtually all pancreatic can-
cers as well as in other epithelial-derived cancers, where it 
serves as a key oncogenic factor, promoting proliferation 
and survival ( 1, 2 ). Despite extensive research, less than 4% 
of patients diagnosed with pancreatic cancer are expected 
to survive past 5 years ( 38 ). Because no RAS inhibitors have 
been effective ( 2, 3 ), current research efforts are focusing 
on targeting deregulated signaling pathways downstream of 
mutant KRAS. The advancement of this therapeutic strategy 
is dependent on a detailed understanding of the complex 
molecular mechanisms underlying signaling events that regu-
late disease progression. 
 NF-κB is known to be constitutively active in a majority 
of pancreatic tumors and pancreatic cancer cell lines, where 
it regulates proliferation, survival, metastasis, and invasion 
( 18 ). NF-κB has also been shown to be activated downstream 
of oncogenic RAS and to promote the oncogenic phenotype 
( 14, 15 ). Thus, the signaling cascades activating the NF-κB 
pathway have become attractive targets for novel chemothera-
peutic approaches in pancreatic and other cancers ( 18 ). There 
is evidence that multiple of arms of NF-κB signaling are acti-
vated in various cancers ( 10 ), thus the ability to block NF-κB 
activity broadly may require multiple inhibitors unless a fac-
tor can be identifi ed that regulates multiple NF-κB–relevant 
signaling pathways. 
 Previous studies from our laboratory and others have 
shown that GSK-3 inhibition reduces pancreatic cancer 
cell viability  in vitro and suppresses tumor cancer cell line 
on June 12, 2013. © 2013 American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from 
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Figure 2.7. Model of GSK-3-NF-κB pathway downstream of mutant KRAS in 
pancreatic cancer. In a normal cell, TAK1-TAB1 complex is minimally active and NF-
κB pathway is dormant. However, mutant KRAS leads to transcriptional upregulation of 
GSK-3α and GSK-3β, that can stabilize TAK1, TAB1 and TAK1-TAB1 complex leading 
to constitutive canonical NF-κB activation. GSK-3α also drives the non-canonical NF-κB 
pathway by promoting/stabilizing nuclear p52, thus leading to constitutive non-canonical 
NF-κB activation. NF-κB drives transcription of genes involved in survival, proliferation, 
metastasis that contributes to an aggressive pancreatic phenotype. 
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 Figure 7.   Model of the GSK-3–NF-κB pathway downstream of mutant KRAS in pancreatic cancer. In a normal cell, the TAK1–TAB1 complex is minimally 
active and NF-κB pathway is dormant. However, mutant KRAS leads to transcriptional upregulation of GSK-3α and GSK-3β that can stabilize TAK1, TAB1, 
and the TAK1–TAB1 complex, leading to constitutive canonical NF-κB activation. GSK-3α also drives the noncanonical NF-κB pathway by promoting/
stabilizing nuclear p52, thus leading to constitutive noncanonical NF-κB activation. NF-κB drives transcription of genes involved in survival, proliferation, 
and metastasis th t contributes to a  aggressive panc eatic cancer phenotype. 
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RAS induce only a selective arm of the NF-κB pathway ( 43, 
44 ), which is different from the well-characterized NF-κB–
regulated pathway downstream of cytokine-induced signal-
ing. NF-κB may also be regulated by upstream activators 
other than GSK-3 in these tumors; thus, inhibiting GSK-3 
alone will not shut down the entire NF-κB signaling pathway. 
 Interestingly, signifi cant changes were observed in long 
noncoding RNAs upon GSK-3 inhibition, which are now 
emerging as key regulators of oncogenesis ( 45 ). We under-
stand that GSK-3 plays important roles in other signaling 
pathways, including Wnt, Notch, and Hedgehog, which have 
been implicated in pancreatic cancers ( 46 ) and which may 
account for the rest of the observed changes in gene expres-
sion. The implications of GSK-3 inhibition on β-catenin sta-
bilization and the Wnt pathway need to be considered ( 46 ); 
however, our encouraging results on tumor growth inhibi-
tion and previous studies strongly support the therapeutic 
potential of GSK-3 inhibitors. 
 Collectively, this report provides the fi rst evidence of the role 
of GSK-3α in promoting oncogenic RAS function through 
the regulation of TAK1–TAB ctivity, upstream of IKK and 
canonical NF-κB pathway, and via control of noncanonical 
NF-κB activity in pancreatic cancer cells ( Fig. 7 ). Importantly, 
these data provide evidence for different roles of GSK-3α and 
GSK-3β in regulating NF-κB signaling in pancreatic cancer 
cells, and highlight the need for the development and testing 
of GSK-3α-specifi c drugs. 
 METHODS 
 Cell Culture and Reagents 
 Panc-1 and MiaPaCa-2 were purchased from American Type Cul-
ture Collection and used for no longer than 6 months before being 
replaced. HPDE cell line (HPDE6) and KRAS4B G12V –transfected 
HPDE (HPDEKR + ) were generous gifts from Dr. Channing Der 
(University of North Carolina-Chapel Hill, Chapel Hill, NC) and 
were maintained in keratinocyte serum-free growth medium. All 
cell culture reagents were obtained from Invitrogen. The follow-
ing antibodies were purchased from Cell Signaling Technology: 
phospho-glycogen synthase (Ser 641 ), glycogen synthase phospho-p65 
(Ser 536 ), p-65, TAB1, TAB2, histone H3, cleaved PARP (Asp 214 ), PARP, 
on June 12, 2013. © 2013 American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst April 1, 2013; DOI: 10.1158/2159-8290.CD-12-0541 
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Supplementary Data - Additional Materials and Methods 
 
Densitomentric analyses and statistics of immunoblots  
Densitometric analyses was performed using adobe photoshop elements 9. The 
signal intensities were normalized to the respective loading controls and then compared 
to the respective control of the experiment. The differences were evaluated using 
Students two-tailed t test and P value <0.05 were considered significant.  
 
Cell cycle analysis  
Panc-1 was seeded at 40,000 cells/6cm plates and treated for 24h with TAK1 
inhibitor, 5Z-7-oxozaenol at the indicated concentrations. For FACS-based cell cycle 
analysis cells were fixed with 70% Ethanol after detachment, followed by centrifugation 
and resuspension in 100µl staining buffer (2% FBS, 1X PBS and 340 µg/ml RNAse) for 
30 minutes at 37°C.  Cells were then stained with 100µl Propidium Iodide labeling 
solution  (50 µg/ml Propidium Iodide ,BD Biosciences) and incubated for 30 min at room 
temperature in the dark. Finally cells were analyzed by flow cytometry using a Beckman 
Coulter CyAn. 
 
Real time RT-PCR 
Total RNA was isolated using RNeasy Plus RNA Isolation kit (Qiagen , 
Germany) according to the manufacturer’s protocol. Reverse transcription was conducted 
using 1 µg of total RNA using MMLV reverse transcriptase (Invitrogen, Carlsbad, CA) 
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according to the manufacturer’s protocol. Real time RT-PCR was then performed using 
TaqMan gene expression assays for Kras, GSK-3α and GusB (Applied Biosystems Inc., 
Forest City, CA) on an ABI 7500 real time PCR system (Applied Biosystems, Inc., Forest 
City, CA). GusB was used as endogenous control and siKras values were normalized to 
siCtrl. 
 
 
 
 
 
Supplemental Figure 2.1 Left: AR-A014418 inhibits GSK-3 activity in a dose 
dependent manner.  Panc-1 cells were treated with increasing concentrations of GSK-3 
inhibitor, AR-A014418, like in Fig.1A. Whole cells extracts were prepared and 
immunoblotted for specified antibodies. p-Glycogen synthase is a downstream substrate 
of GSK-3 and thus an indicator of its kinase activity.  
Right: GSK-3 regulates apoptosis in MiaPaCa-2 cells. Panc-1 and MiaPaCa-2 cells 
were transiently transfected with indicated siRNAs for 72 hours. Whole cell extracts were 
immunoblotted for specified antibodies. 
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Supplemental Figure 2.2A Left: KRAS regulates TAK1 levels. HKRAS cells were 
transiently transfected with non-targeting or KRAS siRNA for 72 hours. TAK1 was 
immunoprecitated from whole cell extracts and immunoblotted for specified antibodies. 
Right: TAK1 inhibition induces apoptosis. MiaPaCa-2 cells were treated with the 
TAK1 inhibitor, 5Z-7-oxozaenol at indicated concentrations for 24 hours. Whole cells 
extracts were immunoblotted with specified antibodies. 
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Supplemental Figure 2.2B. TAK1 inhibition induces apoptosis. MiaPaCa-2 cells were 
treated with the TAK1 inhibitor, 5Z-7-oxozaenol at indicated concentrations for 24 hours. 
Whole cells extracts were immunoblotted with specified antibodies. 
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Supplemental Figure 2.3 TAK1 inhibition decreases cell proliferation in KRAS+ 
cells. Indicated cell lines were seeded in E-plate-16 (Roche) at 3000 cells/well/100µl. 
24hours after plating, cells were treated with TAK1 inhibitor 5Z-7-oxozaenol (0.625µM), 
or vehicle control, DMSO. Cell impedance was measured every 2 hours for the entire 
course of experiment using RTCA. 
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Supplemental Figure 2.4 TAK1 inhibition alters cell cycle regulation. Panc-1 cells 
were treated with TAK1 inhibitor, 5Z-7-oxozaenol or vehicle control, DMSO for 24 
hours. Cells were fixed and stained with Propidium Iodide and analyzed by Flow 
cytometry. 
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Supplemental Figure 2.5 GSK-3 inhibition inhibits TAK1 mediated signaling. Panc-
1 cells were treated with GSK-3 inhibitor, AR-A014418 (30µM) for 24 hours and whole 
cell lysates immunoblotted for indicated antibodies.  
  
P-p38 
p38 
DMSO AR 
Panc-1 
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Supplemental Figure 2.6 GSK-3 inhibition leads to a decrease in TAK1 protein 
Panc-1 and MiaPaCa-2 cells were treated with GSK-3 inhibitor, AR-A014418 or vehicle 
control, DMSO in the presence or absence of MG132 for 24 hours. Whole cell extracts 
were immunoblotted for indicated antibodies.  
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Supplemental Figure 2.7 NF-κB2 depletion leads to increase in PARP cleavage. 
Indicated cell lines were transiently transfected with specified siRNAs, and 72 hours later 
whole cell extracts immunoblotted for cleaved PARP. 
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Supplemental Figure 2.8 GSK-3 inhibition leads to a decrease in TAK1 levels and 
p100-p52 processing in a statistically significant manner. All data obtained with 
independent experiments with Panc-1 and MiaPaCa-2, treated with GSK-3 inhibitor for 
24 hours (right panel) or transiently transfected with indicated siRNA’s for 72 hours (left 
panel) were quantified by densitometric analyses and is expressed as mean±SD. 
Statistical evaluation of the differences were calculated using students two-tailed t test 
and P value < 0.05 was considered significant.  
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Supplemental Figure 2.9 KRAS regulates GSK-3α  mRNA levels. HKRAS cells were 
transiently transfected with non-targeting control or KRAS siRNA. RNA was isolated, 
reverse transcribed to cDNA and real time RT-PCR performed for KRAS and GSK-3α. 
Gus B was used as endogenous control.  
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CHAPTER III 
 
A REQUIREMENT FOR TBK1 IN KRAS-INDUCED LUNG CANCER 
3.1 Summary 
 
KRAS dependent lung cancer cells have been proposed to be addicted to the 
presence of Tank Binding Kinase 1 (TBK1) via regulation of c-Rel activity and basal 
autophagy. However the study of TBK1 function in vivo has been deterred by the 
embryonic lethal phenotype of TBK1 deficient mice. To determine if TBK1 is an 
important regulator of lung tumorigenesis in vivo, we generated a mouse model where 
activation of oncogenic K-RAS in lung cells was coupled with the inactivation of TBK1. 
Using this model system, we show that deletion of TBK1 reduces the number of K-RAS–
induced lung tumors in the absence of the tumor suppressor p53. Loss of TBK1 in the 
neoplastic lesions also led to a reduction in p-AKT, a known regulator of pro-survival 
signaling in oncogensis. These studies demonstrate the importance TBK1 in KRAS-
induced lung tumorigenesis and identify it as a potential therapeutic target for this 
disease.  
 
3.2 Introduction 
 
Lung cancer is the leading cause of cancer-related deaths worldwide (1). Non-
small-cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases, with 
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adenocarcinoma being the major subtype. NSCLC development is associated with 
frequent mutations in a few well-defined oncogenes and tumor suppressor genes. 
Oncogenic mutations in KRAS are found in ∼30% of NSCLCs, c-MYC is up-regulated in 
20%–30%, whereas the tumor suppressor gene p53 is mutated or deleted in ∼50%, and 
the INK4A/ARF locus is often deleted or hypermethylated (2,3). Furthermore, KRAS 
mutations are found in >90% of spontaneous and chemically induced mouse lung tumors 
(2). Such diverse mutations invariably affect responsiveness to standard therapies and 
increase the complexity of effective targeting.  
 
Effective inhibition of KRAS activity has been shown to revert malignant cells to 
a non-malignant phenotype, however cancer therapies aimed at direct inhibition of KRAS 
activity have so far been unsuccessful (4). An alternative strategy to target KRAS-
induced tumors is to identify and target specific molecular vulnerabilities conferred by 
the genetic background of oncogenic KRAS mutations. In this regard, Tank Binding 
Kinase 1 (TBK1) has been identified as a critical regulator of the survival and/or 
proliferation of KRAS mutated NSCLC cells (5-7).  
 
TBK1 was originally described as an NF-κB activating kinase (8) based on the 
fact that mice deficient for TBK1 died from massive liver apoptosis in utero (9), a 
phenotype similar to the mice deficient for p65, IKK-β or NEMO (10). Subsequent 
studies disclosed a crucial role for TBK1 in the innate immune response where it 
activates interferon regulatory factor 3 (IRF3), in response to Toll-like receptor activation 
(10).  Increasing evidence now indicates that aberrant activation of TBK1 is associated 
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with  development of human cancers downstream of oncogenic KRAS. In a systematic 
RNAi screening study Barbie et al., demonstrated that TBK1 is specifically required for 
survival of lung cancer cells harboring oncogenic KRAS mutations (5). The observation 
that TBK1-null mouse embryonic fibroblasts (MEF) displayed increased cell death, and 
decreased cell transformation upon oncogenic RAS expression, further underscores the 
role of TBK1 in tumorigenesis (11). Furthermore, TBK1 has been shown to promote pro-
survival AKT signaling (12,13),  to regulate basal autophagy (6) and to control autocrine 
CCL5 and IL-6 signaling in lung cancer cells (7). Collectively, these studies highlight the 
importance of TBK1 in oncogenesis. However, because of the embryonic death of mice 
with global TBK1 deficiency, the in vivo biological functions of TBK1 have largely 
remained unknown.  Recently two conditional TBK1 deficient mouse models were 
generated to study the role of TBK1 in innate immunity but its role in oncogenesis in vivo 
has not been investigated. 
 
Here, I provide the first description of the role of TBK1 in lung cancer in vivo. 
Preliminary data shows that genetic deletion of TBK1 in KRAS-induced lung cancer 
mouse model reduces lung tumorigenesis in the absence of the tumor suppressor p53. The 
loss of TBK1 led to a reduction in both tumor size and number. Consistent with the 
previous reports of TBK1’s role in promoting AKT signaling, we saw a decrease in 
oncogenic KRAS dependent p-AKT in the transformed lung epithelial cells of TBK1 
deficient mice. Overall, these results show TBK1 as an important KRAS oncogenic 
effector in lung cancer making TBK1 an attractive drug target to approach KRAS related 
malignancies. 
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3.3 Materials and Methods 
 
Generation of TBK1fl/fl C58BL/6 mice  
TBK1 was targeted in E14Tg2a.4 ES cells (derived from the 129P2/Ola mouse 
strain) by a Cre/lox conditional deletion strategy at TransViragen (UNC-Chapel Hill, 
USA) using the TBK1fl construct depicted in Fig. 1A. This TBK1fl construct contains 
LoxP sites flanking TBK1 exon 6 and a NEOR selection cassette. Appropriately targeted 
ES cells were identified by Southern analysis using 5’ external, 3’ external and neomycin 
probes.  The 5’ external probe, produced using primer-1, 5'-
CACGCCCCAACTTTGTTTCC-3', and primer-2, 5'-TGGAAGTCCATACGCATTGG-
3', was hybridized to BamHI-digested genomic DNA, with a 13.1 kb band detected for 
the WT allele and a 9.3 kb band detected for the targeted allele.  The 3’ external , 
produced using primer-1, 5'-CTGTTGTTGCTGTGACAGCC-3', and primer-2, 5'-
CCAGCTTGTTACCCTCTTGC-3', was hybridized to EcoRV-digested genomic DNA, 
with a 19.7 kb band detected for the WT allele and a 16.5 kb band detected for the 
targeted allele. With the neo probe,  produced using primer-1, 5’- 
TGACAATTAATCATCGGCATAGTATATCGG-3’, and primer-2, 5’- 
AAGAACTCGTCAAGAAGGCGATAGA-3’, targeted, unexcised DNA produced a 
12.6kb band and no band was produced with the WT DNA.  ES cells carrying the TBK1fl 
allele were treated with Flp to remove the neo cassette and clones that had neo deleted 
were injected into C57BL/6 blastocysts to generate chimeras that subsequently 
transmitted the TBK1fl allele without the Flp to the F1 generation in crosses with 
C57BL/6 mice. These mice were heterozygous for Flpe and were backcrossed with 
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C57BL/6 to obtain mice carrying TBK1fl allele without Flpe (confirmed using Flp 
genotyping assays as below). To distinguish between WT, targeted (with NEO cassette), 
conditional (without Ne cassette) and deleted TBK1 allele, mice were genotyped by PCR 
of tail genomic DNA using the primers and genotyping assays shown in Table 1. The 
location of each primer with respect to TBK1 allele is shown in Fig.1B. The mice were 
backcrossed to the F6 generation in crosses with C57BL/6.  
 
Generation of KRASLSL-G12D/WTp53flox/flox TBK1fl/fl C57BL/6 mice 
The TBK1fl/fl were crossed with KRASG12D/+ p53fl/fl (KF) mice to 
generate TBK1fl/fl KRASG12D/+ p53fl/fl (TKF) mice. Mice were genotyped by PCR of tail 
genomic DNA using the primers and genotyping assays shown in Table1.  
Animal husbandry and Cre-expressing adenovirus administration 
KRASLSLG12D/WT p53flox/flox mice (14) (2), and mice generated by interstrain 
crossings were housed in pathogen-free conditions according to the protocols approved 
by the University of North Carolina Institutional Animal Care and Use Committee. Lung 
tumor induction was performed by intranasal administration of 1 × 107 plaque-forming 
units of Cre-expressing adenovirus (adenocre; Gene Transfer Vector Core, University of 
Iowa, Iowa City, IA) in selected animals at 8 weeks of age, as described (14). 
Western blotting and immunohistochemistry 
Western blotting and immunohistochemistry were performed as described (14). 
The antibodies used were as follows: anti–phospho-AKT- Ser473 and GAPDH from 
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Santa Cruz; TBK1 and IKKε from Cell Signaling and F4/80 from Abcam. The 
immunohistochemistry slides were scanned and scored using aperio cytoplasmic 
algorithm. This tool scores the intensity of staining in the cytoplasm/nuclei in terms of a 
H-score. H score is calculated using formula: H-Score  = (% at 0) * 0 + (% at 1+) * 1 + 
(% at 2+) * 2 + (% at 3+) * 3. This score produces a continuous variable that ranges from 
0 to 300. 
Histopathologic analysis 
Histopathological analysis was done as described (14). Briefly, mice were 
euthanized by intraperitoneal administration of 250 mg/kg Avertin followed by surgical 
resection of the portal vein. Lungs were perfused with saline and inflation fixed overnight 
with 10% formalin. Fixed tissues were embedded in paraffin, sectioned at 5-µm 
thickness, and stained with H&E. 
Tumor number and grade analysis 
 Tumor slides from each lung lobe (same orientation and level section used for 
each lobe) were scored for number and size blindly using aperio imagescope. 
Detection of Cre-mediated recombination 
Cre-mediated recombination of the TBK1 conditional allele was detected by PCR 
amplification with primers flanking the deleted site (sequences given in table 1). 
Amplification of the wild- type (WT) allele results in a ~2.5kb product, while the 
amplification of the deleted allele results in a 146-bp product . Amplification was 
performed by denaturation at 95°C for 1 minute, followed by 35 cycles of amplification 
at 98°C for 10 seconds, 52°C for 30 seconds, and 72°C for 90 seconds, with a final 
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extension step of 10 minutes at 72°C. 
RNA isolation and real-time PCR analysis 
Total RNA was purified using RNeasy Plus RNA Isolation Kit (Qiagen) as 
previously described (15). Real-time PCR analysis was performed in an ABI 7000 
Sequence Detection System as previously described (16) using Taqman Gene Expression 
Assay primer-probe sets (all from Applied Biosystems) for TBK1 (exon6-7; 
Mm01156588_m1), TBK1 ( exon 4-5 Mm00451150_m1), Relative quantitation was 
determined by the ΔΔCt method using GAPDH (Mm99999915_g1) as the endogenous 
control. 
 
3.4 Results 
 
Generation of TBK1fl/fl mice 
Conventional TBK1-/- mice die at embryonic day 14.5 due to massive liver 
degeneration (9). We, thus, used a conditional deletion strategy, detailed in Fig. 1A to 
create a TBK1-deficient mouse model. 129P2ES cells were generated that harbor a TBK1 
conditional knockout allele (TBK1fl) with LoxP sites flanking exon 6 and a NEOR 
targeting cassette. The NEOR targeting cassette was flanked by FRT recombination sites 
to allow removal by FLPe recombinase. Exon 6 encodes a part of activation loop in the 
kinase domain and upon removal causes a frame shift, leading to complete gene 
inactivation. Appropriately targeted ES cells were electroporated with FLPe recombinase 
to remove the NEOR cassette (17). These ES cells were injected into C57BL/6 blastocysts 
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to generate chimeric mice. Chimeric mice heterozygous for the TBK1fl allele and FLPe 
without the NEOR cassette were mated with a line of transgenic C57BL/6 mice to remove 
FLPe. Progenies of this mating that carry the TBK1fl allele without FLPe and NEOR 
cassette were interbred to produce TBK1fl/fl mice. The resulting TBK1fl/fl mice were 
infected by intranasal administration of adenocre to delete TBK1 specifically in lung 
epithelial cells. To confirm that recombination of the conditional TBK1 allele occurred in 
the lungs of TBK1fl/fl mice, we measured excision by PCR in DNA isolated from whole 
lungs or tails of mice 1 week post-infection (Fig. 2A). A 419-bp product was predicted 
assuming the correct splicing of exon 5 to exon 7 and it was only observed in the DNA 
from lungs of adenocre infected TBK1fl/fl mice (Fig. 2A). However, no change in the 
levels of TBK1 protein was observed by immunoblotting on extracts prepared from 
whole lungs 3 days, 1 week or 2 week post-infection with adenocre (Fig. 3B). This can be 
attributed to the inefficient adenocre infection of lung epithelial cells. RT-PCR performed 
was performed on RNA from the above lungs using primers spanning exons 4/5 or exons 
6/7. The latter revealed a reduction in TBK1-specific transcripts post-infection with 
adenocre (Fig. 2C).  
 
Generation of a TBK1 deficient model of KRAS- induced lung cancer 
To examine the role of TBK1 activity in KRAS- induced lung cancer, we 
generated a mouse model of KRAS and p53– induced lung cancer with loss of TBK1. To 
generate this model, we used oncogenic KRAS–inducible KRASLSL-G12D/WT p53flox/flox 
mice (referred to as KF mice), where expression of oncogenic KRASG12D  is triggered 
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by Cre recombinase-mediated removal of the LSL element with concomitant loss of p53 
floxed allele (2,14,18). Activation of oncogenic KRASG12D induces lung tumor 
formation(2) and the loss of tumor suppressor p53 leads to generation of lung tumors 
with a shorter latency and advanced histopathology (19,20) and does not affect the ability 
of NF-κB to potentiate KRAS-induced lung tumorigenesis (14,21). The KRASLSL-
G12D/WT p53flox/flox mice were then bred to TBK1fl/fl mice to generate TBK1fl/fl KRASLSL-
G12D/WT p53flox/flox (referred to as TKF mice). TKF and KF mice were infected by 
intranasal administration of adenocre to activate oncogenic KRASG12D, inactivate p53 
and TBK1 specifically in lung epithelial cells and induce lung tumor formation. It is 
important to note that only one mouse each for TKF and KF group was used in the 
present study. 
Deletion of TBK1 in the mouse lung decreases KRAS-induced lung tumorigenesis  
Given that TBK1 has been reported to support KRAS-driven oncogenesis 
especially in the context of lung cancer (5,7,11), we asked if genetic deletion of the 
TBK1 gene in the KF mouse model affects KRAS induced oncogenesis. Lungs of KF and 
TKF mice from above, were infected with adenocre to activate K-RasG12D and 
inactivate p53 and TBK1 simultaneously (TBK1Δ/KRASG12D/p53Δ mice). 
As evaluated by pathologic examination of dissected lungs at 13 weeks 
postinfection, TBK1Δ/KRASG12D/p53Δ mouse displays a reduced number of tumors than 
TBK1WT/KRASG12D/p53Δ mouse (Fig. 3A). Interestingly, loss of TBK1 affected not 
only the number of lesions formed but reduced their size and thus the percentage of lungs 
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covered with tumors (Fig. 3B,C). As revealed by immunohistochemical studies, the 
neoplastic lung lesions found in TBK1Δ/KRASG12D/p53Δ mouse lacked TBK1 
expression (Fig. 3D,E) confirming that recombination of the conditional TBK1 allele 
occurred in the lungs of TBK1Δ/KRASG12D/p53Δ mouse. As these results indicate, 
although not absolutely required for tumor formation, TBK1 greatly potentiates KRAS–
induced transformation in the lung in situ.  
Deletion of TBK1 in the mouse lung does not affect the levels of IKKε   
The non canonical IκB kinaseε (IKKε) is the closest TBK1 homolog and has been 
implicated to play an important role in RAS-induced oncogenesis (22,23). Thus, we 
asked if TBK1 loss led to a compensatory increase in IKKε. As seen in Fig. 4, no 
difference was observed in IKKε neoplastic lesions or the whole tissue of 
KRASG12D/p53Δ and TBK1Δ/KRASG12D/p53Δ mice. 
Deletion of TBK1 in the mouse lung decreases p-AKT in KRAS induced lung 
tumors  
AKT signaling is a well established pro-survival pathway downstream of 
oncogenic RAS (3,4). Consistent to activation of KRAS, KRASG12D mice have been 
associated with increased levels of phospho-AKT (14). Recently studies have identified 
AKT as a novel substrate of TBK1 that mediates TBK1’s prosurvival role in oncogenesis 
(12,13). To gain insight into the regulation of AKT by TBK1 in KRAS-induced lung 
tumorigenesis, we investigated if the loss of TBK1 in this mouse model affects p-AKT 
levels. Consistent with previous findings, p-AKT was high in the KRASG12D/p53Δ 
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neoplastic lesions, whereas reduced p-AKT staining was observed in the 
TBK1Δ/KRASG12D/p53Δ lesions (Fig. 5).  
3.5 Discussion and Future Directions 
 
Mutant KRAS occurs frequently in lung cancers where it serves as a key 
oncogenic factor, promoting survival and chemoresistance (3,24).  Despite the presence 
of several targeted therapeutics (EFGR and VEGF inhibitors) lung cancer remains the 
leading cause of cancer related deaths worldwide (1).  Because direct inhibition of KRAS 
has been unsuccessful, current research focuses on oncogenic effectors downstream of 
mutant KRAS, (25-27), (7,21,28).  
TBK1, has been implicated in KRAS driven oncogenesis where it has been shown 
to be required for transformation by oncogenic KRAS(11) , sustain KRAS-dependent 
cancer cell viability (5), and regulate autocrine cytokine signaling (7) and basal 
autophagy (6). Thus TBK1 has become an attractive target for novel chemotherapeutic 
approach in lung cancer and other KRAS driven malignancies. However, studies of 
TBK1 function in vivo have been hindered because of the embryonic death of mice with 
global TBK1 deficiency. Here, we provide the first description of the effect of TBK1 
deletion in a KRAS-induced mouse model of lung cancer.  
Consistent with the previous studies, we show that Cre-generated deletion of 
TBK1 in parallel with KRASG12D activation and p53 deletion in the lung epithelial cells, 
led to reduced transformation as analyzed by tumor number and size (Fig 2).  
Importantly, the loss of TBK1 only reduces, but does not eliminate tumorigenesis 
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downstream of oncogenic KRAS expression. This can be attributed to the incomplete 
deletion of TBK1 gene in the lung, due to the inefficient Cre infection of lung epithelial 
cells. Alternatively, IKKε, the closest homolog of TBK1 may play a compensatory role in 
driving the oncogenesis. IKKε has been shown to be important in oncogenic process 
downstream of KRAS in ways very similar to that described for TBK1 (7,13,29). We 
thus hypothesized that TBK1 loss may lead to an increase in IKKε levels, driving the 
oncogenic signaling in TKF mice. However, we did not observe any difference in IKKε 
levels between KRASG12D/p53Δ and TBK1Δ/KRASG12D/p53Δ mice as measured by 
immunohistochemistry (Fig. 4) suggesting that basal levels of IKKε signaling or other 
pathways activated downstream of KRAS are sufficient to promote lung tumorigenesis in 
the absence of TBK1.  
It is important to note that the KRAS induced lung cancer mouse model used in 
the present study also had a deletion of the tumor suppressor p53. Loss of p53 is known 
to generate tumors faster and of a higher grade but it does not affect the number of 
lesions formed(14,19). Since we observed a reduction in the number of tumors in the 
absence of TBK1 (Fig. 2A), it suggests that TBK1 may play role in KRAS-driven 
tumorigenesis independent of the status of the tumor suppressor p53. However, future 
studies in p53 wild type mice are required to ascertain the effect of TBK1 loss on the 
development of KRAS-induced lung cancer in the presence of p53. 
TBK1 loss also led to a decrease in p-AKT in the neoplastic lesions (Fig. 5), in 
conjunction with the previously described role of TBK1 in promoting AKT signaling 
(12,13). This suggests that downstream of KRAS, TBK1 may be utilizing the pro-
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survival AKT signaling to promote tumorigenesis but will require further studies in more 
animals for confirmation. 
Apart from TBK1, IKKε and AKT, oncogenic mutations in KRAS drive tumor 
growth by engaging multiple downstream pathways, including RAF-MAPK (30), RAL-
GEF (26,27) and inflammatory signals such as NF-κB.  As mentioned above, TBK1 was 
originally described as NF-κB activating kinase, and is also known to activate IKKβ (10). 
Work from our lab and others have previously shown that NF-κB subunits, p65 and c-Rel 
are both important in the survival of KRAS- transformed cells (21,and 28,31). Barbie et 
al., implicated the significance of c-Rel downstream of TBK1 in survival of KRAS 
transformed cells (5). Furthermore, activated NF-κB (p65) has been shown to promotes 
oncogenic process in KRASG12D/p53Δ mouse model (14,21). These studies are 
consistent with a model where both NF-κB subunits would be activated by KRAS to 
promote oncogenesis. Thus it would be important to analyze and compare the activation 
of NF-κB subunits, p65 and c-Rel in the lung epithelial cells of TKF and KF mice post-
infection with adenocre.  
Collectively, this study provides the first evidence of the role of TBK1 in 
promoting KRAS-driven lung cancer in vivo. Although concurrent MAPK/PI3K pathway 
inhibition is under clinical evaluation, multiple approaches are likely necessary to 
identify effective KRAS targeted therapy. In this regard TBK1 seems to be a promising 
drug target to approach KRAS-induced lung cancer because the loss of TBK1 seemingly 
impairs lung tumor formation. This is in agreement with the previous studies implicating 
TBK1 importance downstream of oncogenic KRAS (5-7,11,32). However, due to the 
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limited number of animals used in the study (only 1 per test and control group) further 
studies with more animals need to be done to obtain a statistically significant result. 
Additionally, further studies looking at the activation of NF-κB, cytokine signaling, 
apoptosis and mitotic rate will be required to ascertain the mechanisms employed by 
TBK1 to potentiate transformation.  
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Figure 3.1 Generation of TBK1fl/fl mice.  (A)The structure of the TBK1 gene, the 
targeting vector, the TBK1fl allele, and the deleted TBK1 allele is shown. Yellow box 
indicates the neomycin-resistance cassette which is flanked by FRT recombination sites. 
(B) The location of primers used for genotyping TBK1fl/fl  mice with the presence or 
absence of NEOR and FLPe 
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Table 3.1 Primers used for genotyping TBK1fl/fl mice. The sequence of the primers 
used for genotyping TBK1fl/fl mice with and without NEOR and FLPe and the genotyping 
assays are indicated. 
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Figure 3.2 Characterization of TBK1Δ/Δ mice. (A) TBK1fl/fl  were either infected or not 
infected with adenocre. 1 week post-infection lung and tail genomic DNA was collected 
and subjected to PCR using primers that anneal to exon 6. (B) TBK1fl/fl  and TBK1WT/WT 
mice were infected with adenocre and lung protein lysates were collected at indicated 
time points post-infection and immunoblotted with specified antibodies. (C) TBK1fl/fl  
mice were either infected or not infected with adenocre and RNA collected from lungs at 
indicated time points post-infection was subjected to RT-PCR with primers annealing to 
either exon 4-5 (left panel) or exon6-7 (right panel) of TBK1 gene.  
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Figure 3.3 Deletion of TBK1 in the mouse lung decreases KRAS-induced lung 
tumorigenesis TBK1Δ/KRASG12D/p53Δ (TKF)and KRASG12D/p53Δ (KF) mice were 
analyzed 13 weeks post-infection. (A) number of K-Ras–induced neoplastic lesions was 
determined by counting lesions in H&E-stained lung sections as described (see Materials 
and Methods). (B) Total tumor area was divided by the whole tissue area to determine the 
tumor spread over the tissue. (C)Average size of the neoplastic lesions was calculated as 
described (see Materials and Methods) (D) immunohistochemistry for TBK1 (positive 
cells are shown brown) and its quantification (lower panel). 
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Figure 3.4. Deletion of TBK1 in the mouse lung does not affect the levels of IKKε  
TBK1Δ/KRASG12D/p53Δ (TKF) and KRASG12D/p53Δ (KF) mice were analyzed 13 
weeks post-infection by immunohistochemistry for IKKε (positive cells are shown 
brown) and the data was quantified as described (see Materials and Methods) 
 
 
 
 
 
 
 
Figure 3.5. Deletion of TBK1 in the mouse lung decreases p-AKT in KRAS induced 
lung tumors TBK1Δ/KRASG12D/p53Δ (TKF) and KRASG12D/p53Δ (KF) mice were 
analyzed 13 weeks post-infection by immunohistochemistry for p-AKT (positive cells are 
shown brown) and the data was quantified as described (see Materials and Methods) 
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CHAPTER IV 
 
 
CONCLUSIONS & FUTURE DIRECTIONS 
 
The goal of this research has been to investigate novel and effective drug targets 
in KRAS-driven malignancies by understanding the complex signaling pathways 
downstream of KRAS that promote disease progression.  
KRAS is the most frequently mutated oncogene in human cancers and has thus 
been a “target” for cancer biologists since its discovery 30 years ago.  Yet in 2014, there 
are no drugs that target KRAS protein directly or act on KRAS induced tumors. Indeed, 
KRAS-driven tumors remain the most difficult to treat, for example lung and pancreatic 
cancer, which are the foremost and fourth leading causes of cancer related deaths in the 
United States, respectively (1). Previously, we and others have demonstrated the 
importance of NF-κB in promoting oncogenesis downstream of mutant RAS (2-6). 
Furthermore, NF-κB has been observed to be active in tumor biopsies from KRAS 
induced lung cancer patients, (7), in KRAS positive prostrate epithelial cells (8) and in 
both pancreatic cancer cells and melanoma in a RAS dependent manner (9,10). Several 
other candidates have emerged as important mediators of the transforming effects of 
oncogenic RAS, including the kinases TGF-β activated kinase 1 (TAK1) (11,12), 
glycogen synthase kinase 3 (GSK-3) (13,14) and Tank Binding Kinase 1 (TBK1) (15-17). 
Interestingly the transcription factor, NF-κB is known to be regulated by all the above-
mentioned kinases but the mechanisms are not clear in the context of specific 
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malignancies.  
Chapter two underscores the oncogenic role GSK-3α plays in pancreatic cancer. 
Consistent with previous reports (18,19), our data indicates that GSK-3 drives 
constitutive, pro-survival NF-κB activity in pancreatic cancer. The primary focus of this 
project was to dissect the individual roles of the two isoforms- GSK-3α, GSK-3β in 
regulating NF-κB activity in pancreatic cancer cells. Our data provides the first evidence 
for a role of GSK-3α in regulating pro-survival NF-κB activity in pancreatic cancer cells 
(see Figure 2.1). Our data suggests that TAK1 is constitutively activity in pancreatic 
cancer cells and plays a role in maintaining constitutive NF-κB signaling (see Figure 
2.2).  Importantly, we propose that GSK-3α may be linked to constitutive IKK and NF-
κB through the stabilization of TAK-TAB complex (see Figure 2.3).  We observed a 
reduction in TAK/TAB levels following GSK-3 inhibition in both pancreatic cancer cell 
lines as well as human pancreatic tumor explants. However, further studies are needed to 
establish the mechanistic link between GSK-3α and TAK1. One possible hypothesis is 
that GSK-3α phosphorylates TAB1/TAB2 that leads to the activation/stabilization of 
TAK/TAB complex in KRAS positive pancreatic cancer cells. This hypothesis is based 
on the finding that TAB1 and TAB2 contain multiple GSK-3 consensus motifs (20) and 
should be addressed in future studies. Thus our in vitro studies identify TAK1 and GSK-
3α as potential drug targets in pancreatic cancer. Future studies evaluating the effects of 
TAK1 inhibitor and GSK-3α specific inhibitor on the development/maintenance of 
pancreatic tumor in vivo would lay the path for the development of these drugs for 
clinical use. 
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Previous studies looking at GSK-3 and NF-κB activity have invariably focused on 
the canonical NF-κB pathway (18,21). However, our data provides the first description 
for the role of GSK-3α in regulating pro-survival non-canonical NF-κB in pancreatic 
cancer cells and pancreatic tumor explants. Further studies are required to address the 
mechanism of how GSK-3α affects processing of the non-canonical NF-κB subunit, 
p100 to its active form p52. Since we observed a distinct effect of GSK-3α on nuclear 
p52 (See Figure 2.4) and since GSK-3 is known to accumulate in the nucleus of 
pancreatic cancer cells (14), two possible explanations exists: (1) nuclear GSK-3α 
regulates nuclear p100 processing or (2) GSK-3α affects the nuclear transport of  p52. At 
the time of these studies, a GSK-3α specific drug was unavailable commercially, and 
thus we performed our human tumor explant study with a pan-GSK-3 inhibitor. We 
observed a 50% tumor growth inhibition in the presence of a GSK-3 inhibitor with a 
concomitant decrease in expression of several NF-κB target genes (see Figure 2.5, 2.6).  
However in the light of the above study, there is a definite need to develop a GSK-3α 
specific drug and determine its effect on pancreatic cancer in vivo. We used a tumor 
explant xenograft model for our studies but it would be interesting to compare these 
results in a genetic model of pancreatic cancer in mice. 
Collectively, the studies in Chapter 2 identify two novel drug targets in pancreatic 
cancer- TAK1 and GSK-3α.  TAK1 was recently identified as an important mediator of 
cell survival in KRAS dependent colon cancer (11) and of chemoresistance in pancreatic 
cancers (12). Our study not only confirms their findings but builds on to it by adding 
GSK-3α as an important kinase upstream of TAK1. Thus it is possible that the 
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chemoresistance conferred by TAK1 in pancreatic cancer cells or the regulation of cell 
survival by TAK1 in colon cancer cells is controlled by GSK-3α. The testing of this 
hypothesis will need to be done in future studies and may potentially find a universal 
mediator of KRAS oncogenic roles in GSK-3α.  
Another kinase which has recently been implicated in KRAS-driven oncogenesis 
is TBK1 (15,16,22). TBK1 was originally identified as an NF-κB activating kinase which 
functions as a key regulator of innate immunity. We provide here the first description of 
the oncogenic role of TBK1 in vivo using a conditional TBK1 knockout mouse model. A 
KRAS/p53 driven lung cancer mouse model (2,3) was used to induce lung tumors with a 
concomitant loss of TBK1 in the lung epithelial cells. We observed a reduction in tumor 
size and numbers upon the loss of TBK1 in the lungs (Figure 3. 3) identifying TBK1 as a 
promising drug target in KRAS positive lung cancers. The major caveat of this study was 
the number of animals used  (only 1) and thus it is essential to expand the number of 
animals to ascertain a statistically significant role of TBK1 in promoting lung tumor 
number and size. Furthermore the mechanisms employed by TBK1 to promote lung 
tumors need further investigation. In this regard we can investigate the effect of TBK1 
loss on mitotic and apoptotic rate, NF-κB and cytokine signaling in KRAS/p53 and 
KRAS driven lung tumors.  
Our studies used a KRAS/p53 driven lung caner mouse model but it is possible 
that the role of TBK1 in lung cancer may be dependent on the p53 status. Previous 
studies have shown that p53 leads to development of tumors fasters and of a higher grade 
(23). NF-κB has been shown to be important in lung tumorigenesis irrespective of the 
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p53 status (2) but whether TBK1’s role in lung tumorigenesis is dependent on the 
presence/absence of p53 needs to be tested as this will be a very important in designing 
personalized therapy for patients. Thus, future studies looking at the effect of knocking 
out TBK1 and activating KRAS mutation on lung tumorigenesis in the lungs of mice with 
wildtype p53 are required.  
Our preliminary data suggest that TBK1 is important in initiation and 
development of KRAS positive lung tumors. However, whether TBK1 is required for 
maintenance of these lung tumors is a different question and needs to be addressed for 
any therapeutic application. To address this question we can use TBK1 inhibitors in a 
KRAS or KRAS/p53 driven lung cancer mouse model. Once the tumors reach a 
measurable size in these mice models, the mice can be treated with TBK1 inhibitors and 
monitored for the growth of the tumor over time. Simultaneously the effect of TBK1 
inhibitor needs to be tested in vitro in KRAS mutant lung cancer cell lines and cell lines 
derived from the above induced tumors. If the data from above studies supports the 
hypothesis that TBK1 is important in development and/or maintenance of KRAS mutant 
lung tumors, it may be worth while to develop a knock-in mouse model of kinase dead 
TBK1. This inactive TBK1 mouse model can be used to assess the initiation/development 
of tumors in a KRAS driven lung cancer model. The absence or decrease in lung tumors 
in the presence of kinase dead TBK1 will confirm the importance of TBK1 kinase 
activity in lung tumor development. These results will definitely support the development 
of specific and potent TBK1 inhibitors for pre-clinical and clinical studies. 
Chapter two uncovered a role of GSK-3α in regulating two arms of pro-survival 
NF-κB (canonical and non-canonical) while chapter 3 investigated the oncogenic role of 
 124 
another NF-κB activating kinase, TBK1. Additionally there is some preliminary data that 
suggests a link between GSK-3α and TBK1- leading us to hypothesize that GSK-3α sits 
on top of multiple of NF-κB signaling downstream of mutant KRAS and thus blocking 
GSK-3α can affect oncogenesis via inhibiting multiple downstream pro-survival 
pathways. This hypothesis is currently being tested in vitro using TBK1 null MEFs and 
multiple KRAS mutant cancer cells. The availability of TBK1 conditional knockout mice 
will allow to study this question in vivo by looking at the effect of TBK1 knock-out on 
GSK-3α expression, or effect of GSK-3 inhibitors on development of lung cancers on 
TBK1 null/KRAS mutant background. 
Apart from the cancer-related implications, our study also has implications in the 
realm of immunology. TBK1 is known to be important in an anti-viral response but the 
absence of a TBK1-null mouse has been a hindrance in evaluating its role in vivo. 
Availability of a conditional TBK1 knockout mouse will help address this question. 
Additionally the phenotype of TBK1 null mice (embryonically lethal due to liver 
apoptosis (24) is not clearly understood. Initially the effect was attributed to impaired 
NF-κB signaling in TBK1 null mice. However it has been shown that TBK1 is not 
essential for NF-κB signaling (25). Thus further studies are needed to determine the 
mechanisms behind the embryonic death of TBK1 null mice, which can now be 
conducted in the TBK1 conditional knockout mouse. 
Taken together, the previous chapters identified and proposed several novel drug 
targets for KRAS- driven malignancies- including, TAK1, GSK-3α and TBK1. Further 
investigation into the effects of specific inhibitors of these on KRAS induced tumors in 
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vivo is required to determine the clinical potential of these targets. KRAS driven tumors 
are one of the most therapy-resistant tumor with high mortality rates and thus there’s 
need to identify and develop novel therapeutics. Although concurrent MAPK/PI3K 
pathway inhibition is under clinical evaluation, multiple approaches (like those 
investigated in this project) are likely necessary to identify effective KRAS targeted 
therapy. The implications of these results go way beyond pancreatic and/or lung cancers 
and extend to other KRAS mutant cancers, including colorectal cancer, breast cancer, 
seminoma among others. Thus future studies focusing on other KRAS tumors may 
identify TAK1, GSK-3α and TBK1 as important mediators of KRAS oncogenic 
signaling in all KRAS tumors. It will be interesting to observe and compare the effects of 
TAK1/GSK-3α/TBK1 kinase inhibitors alone and in combination in various KRAS 
mutant tumors and cell lines. These studies will answer questions like 1) Do 
TAK1/GSK3/TBK1 act in a same pathway to control cell survival or do their inhibitors 
have an additive effect? 2) Are GSK3/TAK1/TBK1 inhibitors are tumor suppressive in 
all KRAS mutant tumors or only specific ones? 3) Do GSK-3/TAK1/TBK1 inhibitors 
have a synergistic effect with current chemotherapeutic agents?  
In conclusion these results have laid the foundation for development of multiple 
drug targets and future investigations into the effects of TAK1/GSK-3α/TBK1 targeting 
on KRAS driven malignancies are required to determine if the benefits outweigh the 
costs of these novel therapeutics.  
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